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Incremental decreases in the low abundance telomerase RNA (TR) cause short telomere 
syndromes, the most common of premature aging disorders. Thirteen genes have been 
shown to cause the short telomere syndrome phenotype (STS) and six of them (46%) 
disturb telomerase RNA (TR).  In addition to TR itself, mutations in DKC1, NOP10, NHP2, 
PARN, and as we recently found, NAF1, all disturb TR integrity pointing to TR 
abnormalities as the most commonly perturbed pathway in human short telomere 
syndromes. To test how mutations in NAF1, a box H/ACA RNA ribonucleoprotein, cause 
phenotypes such as pulmonary fibrosis, emphysema and bone marrow failure, we used 
CRISPR/Cas9 to disrupt the Naf1 locus in mice and found that Naf1 was essential.  
However, Naf1+/- mice survived and showed haploinsufficiency for TR.  Moreover, Naf1+/- 
mice showed a similar decrease of sno- and sca- H/ACA RNA levels as with TR.  However, 
we did not observe any phenotypic abnormalities in these mice including no phenotypic 
evidence of a ribosomopathy such as hematologic, skeletal or neurologic defects. In a high 
resolution analysis of 82 ribosomal pseudouridylation sites in ribosomal RNA components, 
28S, 18S, 5.8S, using Pseudo-Seq, we found no abnormalities in Naf1+/- mice.   These data 
indicate that although the levels of box H/ACA RNAs are compromised in Naf1+/- mice, 
they are sufficient to direct pseudouridylation and maintain ribosome function.  In contrast, 
NAF1 mutations cause TR haploinsufficiency, telomere shortening, and telomere-
mediated disease. To identify additional novel genetic causes of STS and TR insufficiency 
we used genome-wide linkage and identified heterozygous loss-of-function mutation in 
ZCCHC8, a nuclear RNA exosome targeting component. We show that ZCCHC8 is 
 iii 
required for telomerase function by targeting a longer nascent TR to the RNA exosome for 
3’end maturation.  Zcchc8+/- mice had low TR levels and defective TR 3’ends, but their 
transcriptome was otherwise preserved.  In contrast, Zcchc8-/- mice showed a progressive 
fatal neurodevelopmental phenotype that resembled a ciliopathy. Their transcriptome was 
highly dysregulated with 3’end misprocessing of low abundance intronless RNAs that were 
similar in length to TR including replication-dependence histones.  Our data underscore 
the dosage sensitivity for telomere maintenance not only to TR levels but also to the levels 
of some of its biogenesis factors and indicate that vertebrate TR shares a 3’end processing 
pathway with a subset of low abundance RNAs, including replication-dependent histones.  
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intronless (42 of 188 with known gene structure, 22%). The pie charts divides the intronless genes by 
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https://www.ncbi.nlm.nih.gov/gene, accessed 1/1/2019) between 400 and 560 (22 of 28).  The 3’ and 
5’end analyses denote longer ends at each of these mature RNA boundaries in Zcchc8-/- as manually 
visualized in Integrative Genomic Viewer (IGV).  Columns refer to 5’end and 3’end refer to presence 
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Telomerase is limiting 
Telomeres are the repetitive DNA sequences capping the ends of chromosomes ensuring 
end-replication does not interfere with genome stability. Telomerase functions to 
synthesize new telomere repeats. It has two essential components: the telomerase reverse 
transcriptase (TERT) catalytic component and a telomerase RNA (TR) template (1, 2). 
Telomere length is exquisitely sensitive to perturbations in these two essential 
components, and disruption in the availability of either component leads to telomere 
shortening (3, 4). Loss of TERT and TR lead to haploinsufficiency for telomere 
shortening in yeast, mice, and humans (5-10). In humans 6 of 13 disease genes including 
either TR itself or TR-related proteins have be found to be mutated in short telomere 
syndromes (STS) (11). However, despite advances in genome-wide sequencing and 
targeted next-gen sequencing of these known genes, a significant fraction of sequenced 
families in the Johns Hopkins short telomere registry have low TR levels without 
identifiable mutations in known genes. Causative mutations in these families could be 
evasive, deep intronic and other non-coding changes affecting known genes that are yet 
to be uncovered. Alternatively, they could be mutations in novel genes with roles in TR 
RNA biogenesis. Screens for genes critical for telomere length regulation in yeast suggest 
a significant fraction of telomere length regulating genes (one-third) are involved in RNA 
metabolism, leading us to hypothesize that unsolved human families with STS especially 
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those with aberrant TR levels have mutations in genes involved in RNA biogenesis 
critical for stability, processing, or maturation (Figure 1) (12, 13).  
 
 
Figure 1. Genes identified as regulators of telomere length in yeast. Unique genes were identified 
as having roles in telomere length regulation after review among three independent gene deletion, 
haploid, and essential gene screens for telomere length maintenance in Saccharomyces cerevisiae (12-
14). A total of 166 genes were grouped into 10 categories and the frequency of genes in each category 
is represented here in this pie chart. 
 
Mutations in TR-related proteins cause dose-dependent clinical manifestations  
 
Mutations in TR-related proteins cause clinical manifestations of short telomere 
syndromes specifically due to perturbations in mature TR levels that lead to telomere 
shortening. It is the telomere length and not telomerase RNA levels that influence disease 
as has been shown in mice. Loss of TR in both TR-/- and TR+/- mice causes telomere 
length shortening across generations leading to decreased survival in late-generation mice 
and tissue renewal defects as shown in intestinal epithelium, testes seminiferous tubules, 
bone marrow, and peripheral blood. These mice show anticipation of short telomere 
disease as seen in humans, with more accelerated shortening in TR-/- compared to TR+/- 
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mice that reflects a dose-dependent relationship between TR levels and disease severity 
(6, 15). This dose-dependent relationship with disease severity also exists for TR-related 
proteins mutated in humans. Individuals with heterozygous loss-of-function mutations in 
nuclear assembly factor 1, NAF1, and poly(A)-specific ribonuclease, PARN, are 
haploinsufficient for TR and develop short telomere syndromes (16-18). Biallelic 
hypomorphic PARN mutations also cause a more severe disease, Hoyeraal-Hreidarsson 
syndrome (HHS), with clinical manifestations including severe bone marrow failure, 
immunodeficiency, developmental defects and cerebellar hypoplasia (Table 1) (17, 19). 
No biallelic NAF1 mutations have been identified yet to date, but in this work we 
engineered mice with a null NAF1 allele to examine the molecular consequences driving 
disease upon NAF1 loss. We found TR levels were disrupted in Naf1+/-  mice but had 
intact pseudouridylation whereas Naf1-/-  mice were embryonic lethal, underscoring the 
exquisite sensitivity of TR levels to this dose-dependent mechanism for disease severity. 
Further, we found that heterozygous loss of function mutation of a novel gene, ZCCHC8, 
in familial short telomere syndrome disrupts TR 3’ end processing and maturation. We go 
on to show that complete loss of ZCCHC8 in knockout mice causes a more severe 
neurodegenerative phenotype than ZCCHC8 heterozygous loss in which mice develop 
only a telomere phenotype. The fact that heterozygous loss of TR-related proteins cause 
only short telomere disease support the idea that non-telomeric functions of those 
proteins are only perturbed upon biallelic loss causing more severe phenotypes such as 





TR sequence, structure, and ribonucleoproteins are highly divergent across species 
Although the requirement for a reverse transcriptase and RNA template essential for 
telomere elongation in humans, yeast, and many other lower organism was discovered 
and first characterized in cilia (2, 20), TR is highly divergent in sequence and structure 
across phylogenetic kingdoms which complicates the utility of identifying homologous 
TR ribonucleoproteins bound to these RNAs in lower organisms specifically as candidate 
genes to inform vertebrate TR biogenesis. The distinct secondary structures in each 
species require a unique collection of ribonucleoproteins for maturation and stability 
which may contribute distinct 3’-end processing mechanisms. Cilia have the shortest 
telomerase RNA. tTER in T. thermophilia is only 159 bp and bound by p65 which 
interacts with p75, p50, p45, and p19 proteins for stability and Teb1 recruitment for 
telomere lengthening. TER1 and TLC1 in S. pombe and S. cerevisiae respectively are 
much longer (>1,200 nucleotides) requiring “long range” base-pairing in 3 stems and 
additional ribonucleoproteins for stability. Both TLC1 and TER1 are bound by Sm 
proteins and Est1; however, TLC1 is additionally bound by Pop1, Pop6, and Pop7, the 
Ku 70/80 complex, and Est2 indirectly bound with Est3. Human TR ribonucleoproteins 
are altogether different than cilia and yeast as it has evolved from yeast to contain a 
H/ACA domain which is bound by Dyskerin complex at the 3’end (21, 22).  Interestingly 
Gene Heterozygous mutations Biallelic mutations 
TR Short telomere syndrome Dyskeratosis congenita 
NAF1 Short telomere syndrome None reported 
PARN Short telomere syndrome Dyskeratosis congenital and HHS syndrome 
ZCCHC8 Short telomere syndrome ? Neurodevelopmental defect 
 Table 1. Dose-dependent manifestations of mutations in TR and TR proteins.  
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although lower organism TRs do not have H/ACA motifs, there are small nucleolar (sno) 
and small Cajal body associated (sca) RNAs in yeast that do have H/ACA motifs which 
have informed vertebrate TR biogenesis. For example, the only human proteins with 
yeast homologs that have been identified in short telomere syndrome are proteins 
essential to H/ACA biogenesis including DKC1, NAF1, and PARN. Studies of these 
proteins in yeast sno- and sca- RNA maturation has shed light on mechanism for 
vertebrate telomerase H/ACA stability and processing at the 3’end (21).  However  
 despite these differences and insights from yeast, many questions remain regarding the 
mechanisms for vertebrate TR processing at the 3’end and its interaction, if any, with the 
5’ end. Do the distinct ribonucleoproteins in each species dictate a distinct 3’end 
processing mechanism and are there any similarities in 3’end processing of the lower 
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End processing of 3’ extended TR has evolved as a step towards maturation 
 
In addition to these differences in structure and binding proteins, the 3’end processing 
mechanisms and involved proteins among cilia, yeast, and humans also vary widely. Cilia 
require no 3’end processing as tTER ends in a polyuridine tail that requires no further 
maturation. In yeast, S. pombe utilizes the spliceosome for endonucleolytic cleavage of 
nascent TER1 to its mature form whereas S. cerevisiae coopts the RNA exosome for 
TLC1 exonuclease trimming mediated by Nrd1-Nab3-Sen1 complex that is limited by the 
RNA bound Sm proteins (Table 2) (23-25). A poyladenylated 3’extended TLC1 exists 
and comprises a small percentage (<10%) of the total RNA; however polyadenylation is 
not required for maintaining mature levels which suggests the polyadenylated form is not 
a mature TR precursor and is dispensable for telomere length maintenance in S. cerevisae 
(26). Similarly, a  3’ extended polyadenylated form of human telomerase RNA (hTR) 
also exists, but in contrast to S. cerevisae, disruption of polyadenylation due to mutations 
in the polyadenylase PARN decreases the total fraction of mature 451 nucleotide hTR 
leading to telomere length shortening and subsequently disease in humans (Table 2) (16, 
17, 27). To date, the mechanism of hTR processing to the mature form with a shorter 
3’extended polyadenylated intermediate processed by PARN remains poorly understood. 
The mechanism of PARN dependent maturation of the 3’ end of RNAs, in particular 
snoRNA H/ACAs, was first described in U2OS cancer cells (28) and 3’ RACE deep 
sequencing first used to identify a population of oligoadenylated human TR in HEK293T 
cells (29) before the these findings and methods were adapted to describe PARN 
dependent TR maturation in induced pluripotent stem cells from patients with biallelic 
PARN mutations and STS (17). Nascent TR forms greater than 1000 nucleotides exist 
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(30) but how and whether these are intermediates are processed to the mature forms has 
remained elusive. In this work, we propose ZCCHC8 targets these long 3’ extended 
nascent TR forms to the RNA exosome for 3’ exonucleolytic trimming to mature or near-
mature TR forms that can become polyadenylated and matured by PARN. We use genetic 
studies in familial short telomere syndromes and functional studies utilizing 3’end 
sequencing technologies in cell lines to provide insight into the mechanisms of 3’end TR 
processing by establishing a role for the RNA exosome in maturation as in S. cerevisiae 
via a nuclear exosome targeting complex.  
 
Vertebrate TR transcription could be coupled to the RNA exosome and dependent 
on localization  
Unlike sno- and sca- H/ACAs which are excised from introns of mRNA genes, TR is 
transcribed from its own promoter and locus and because it is matured starting from its 
own transcriptional unit, it is plausible that the 5’ and 3’ end processing have distinct 
features from other H/ACAs and are possibly even coupled by yet to be determined 
mechanisms (31). Human and yeast TR biogenesis starts with transcription by RNA pol 
II. Both mouse and human TR contain promoter features typical of other pol II mRNAs 
including a TATA box and consensus CCAAT sequence (32). Transcription includes 
addition of a 5’ monomethylated cap of TR that is subsequently trimethylated by TGS1 
which has been shown to be localized at the Cajal body (33-35). The methylated cap 
serves a number of roles for RNAs during transcription including interaction with the 
Cap Binding Complex (CBC) which consist of the cap proteins CBP20 and CBP80. The 
CBC is recruited by RNA pol II to the 5’ cap of nascent RNA to support protection, 
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transcription, termination, and 3’end formation of nascent RNAs. It carries out these 
functions, including 3’end formation, by recruiting other RNA processing factors 
including the snRNA trafficking protein PHAX and the Nuclear RNA EXosome 
Targeting (NEXT) complex via the zinc finger RNA exosome mediating protein, 
ZC3H18 (36-38).  The PHAX snRNA export protein has also been shown to bind TR 
within the nucleus, but how it contributes to maturation has not been explored (39). The 
CBC complex has recently been implicated in TR processing as extended nascent TR 
precursors accumulated upon transient knockdown of CBP80 in HeLa cell lines (40). 
However, little evidence exists to date supporting a mechanism by which the CBC 
contributes to TR maturation specifically through coupling to the NEXT complex and 
RNA exosome at the 3’end. The RNA exosome has also been linked to TR degradation 
via the TRF4/AIR2/MTR4 polyadenylation (TRAMP) complex (30, 40). Studies suggest 
the TRAMP complex acts to degrade RNA via the RNA exosome in the nucleoli. The 
NEXT complex and DIS3 RNA exosome exonuclease are localized in the nucleoplasm 
and its role in TR maturation has not been explored (37). Overall, subcellular localization 
of RNA exosome components could be a determinant of maturation via the NEXT 
complex and DIS3 verses degradation in the nucleoli via the TRAMP complex. In this 
thesis we show that the NEXT complex component ZCCHC8 is required for TR 3’end 
formation, and it is plausible that this 3’ end maturation via the NEXT complex is 
dependent on coupling to CBC at the 5’-end at the trimethyl cap. Testing of this 
hypothesis and mechanism will be the subject of future investigation. 
 
The data in this thesis support this model for vertebrate TR 3’end processing  
 
 9 
In summary, we utilized using genome-wide linkage in a family with short telomere 
syndrome to identify a new gene, the NEXT complex component ZCCHC8, which 
targets human TR to the RNA exosome for maturation. We propose a model in which 
nascent TR is transcribed by RNA polymerase II to an extended precursor as long as or 
greater than 1000 nucleotides which requires exonucleolytic trimming to the most 
common mature 451 nucleotide form. The extended nascent TR is recruited to the RNA 
exosome for processing to the shorter mature form for by the NEXT complex in the 
nucleoplasm via ZCCHC8 binding, potentially by coupling to the CBC at the 5’ 
trimethylguanosine cap. Near-mature polyadenylated nascent forms (less than 10-15 
nucleotides extended) are subsequently processed by PARN to the mature form. The 
Dyskerin complex binds TR at the H/ACA domain to provide stabilization as NAF1 
traffics TR to the Cajal body where it is exchanged with GAR1 for subsequent 
recruitment of TERT and trafficking to the telomere for telomere elongation (Figure 2). 
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Figure 2. Model for hTR biogenesis and processing. hTR is transcribed from its own promoter (right 
angle arrow) by RNA polymerase II (pol II). Post-transcriptional stability is provided by binding of the 
Dyskerin complex to the TR box H/ACA motif. The Dyskerin complex also includes NAF1, NHP2, and 
NOP10. End processing at the 5’ and 3’ end is shown (large curved arrows). TGS1 trimethylates the 5’ 
trimehthylguanosine cap (TMG) which may be coupled to the cap binding complex (CBC) to assist in 3’ 
end processing (dashed arrow).  Extended nascent TR transcripts as long as or greater than 1000 
nucleotides (nt) are either targeted for maturation via binding by ZCCHC8 and the NEXT complex to the 
RNA exosome bound by the exonuclease DIS3 in the nucleoplasm or targeted for degradation via the 
TRAMP complex to the RNA exosome in the nucleolus. After trimming by the RNA exosome, shorter 
adenylated nascent TR forms (abbreviated with line and short polA tail) are processed further by the 
deadenylase PARN to the most common mature TR form that is 451 nt and bound by the Dyskerin 
complex. NAF1 traffics TR to the Cajal body where it is exchanged with GAR1. 
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INTRODUCTION 
Telomerase is a ribonucleoprotein consisting of both an essential reverse transcriptase 
(TERT) and integral RNA component (TR) that are necessary for telomere elongation 
during replication (2, 20). Additional proteins are important for telomere maintenance, 
recruitment of telomerase for elongation, and telomerase RNA biogenesis and trafficking, 
and 13 of these genes have previously been linked to short telomere syndromes including 
ribonucleoproteins of the dyskerin complex dyskerin itself, NOP10, and NHP2 (41). 
Almost a decade ago, the discovery was made that inherited short telomeres can manifest 
as pulmonary fibrosis with the discovery of germline mutations in TERT and TR in 
familial disease(9). More recently short telomeres and mutations in TERT and have also 
been found in severe cases of COPD (42).   
 
Recently, using a candidate gene approach as previously described, we have uncovered 
heterozygous, frameshift mutations in nuclear assembly factor one, NAF1, in both a 
familial and sporadic case of pulmonary fibrosis and short telomeres (18). NAF1 is a 
ribonucleoprotein that associates with the dyskerin complex and has been shown to be 
important for box H/ACA RNA stability (43, 44). Small nucleolar (sno-) and small Cajal 
body (sca-) RNAs containing H/ACA box domains have multiple functions including one 
of the most frequntly described roles in guiding site-specific pseudouridylation of 
ribosomal, spliceosomal, and messenger RNAs, an enzymatic process shown in some 
cases to be important for ribosomal integrity and translation at the ribosome. (45, 46). 
Similar to these sno- and scaRNAs, TR contains an H/ACA box domain previously 
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shown to be essential for its stability and localization in the Cajal bodies, and mutations 
in this domain are known causes of disease (8, 47-53).  
 
We studied null NAF1 mutations in families with low TR, short telomeres, and 
pulmonary fibrosis. Lymphoblasts from cases having the familial NAF1 mutation had 
reduced NAF1 levels, were haploinsufficent for TR, and had telomere lengths measuring 
below the 1st percentile. Additionally, TR levels were reduced upon NAF1 knockdown in 
HeLa cells and a homozygous knock-in model of the familial NAF1 mutation in HCT116 
cells dramatically decreases TR levels (18). Here, we generated mice heterozygous for a 
null mutation in Naf1 and show that haploinsufficiency of Naf1 in these mice leads to a 
marked reduction in TR levels, but no reduction in pseudouridylation at sites (Ψ) in 
ribosomal RNA (rRNA) despite a trending reduction in a select group of guide H/ACA 
RNAs targeting these sites.  Further, we show despite the decreases in TR, snoRNAs, and 
scaRNA levels, these mice have no clinical pathologies and NAF1 null mice were 
embryonic lethal likely due to disruption pseudouridylation and rRNA stability. These 
findings suggests that the telomerase is sensitive to NAF1 dosage and the phenotype 
associated with loss of NAF1 is a telomere syndrome and does not cause pathologies due 
to disruptions in rRNA biogenesis. 
RESULTS 
Decreases in mammalian NAF1 result in decreased TR levels 
 
Naf1p is essential in yeast (Fatica, Capozzo, Dez); however, its essential role in 
mammalian systems has yet to be described. What is known has been limited to its 
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function in maintaining small H/ACA RNA levels in yeast and HeLa cells. Given our 
interest in the regulation of telomerase RNA which also contains a box H/ACA, and to 
ascertain its essential role in mammals, we used CRISPR/Cas9 technology to create null 
alleles in the mouse. We first tested this model in mouse embryonic fibroblasts (MEFs). 
We designed an sgRNA and DNA oligo for homology directed recombination (HDR) to 
target and edit a locus in exon 1 of Naf1, that would simultaneously introduce a stop 
codon and alter an endogenous SacII restriction cut site to NaeI. A restriction digest and 
gel electrophoresis were used to screen for clones with editing, followed by Sanger 
sequencing. Digest of the 838 base pair (bp) into a 599 bp and 239 bp band indicated 
cutting. Cutting with SacII restriction digest to two bands indicated the presence of a WT 
allele while cutting with NaeI indicated the presence of a correctly edited, null allele 
(Figure 3a). A CRISPR/Cas9 vector containing the sgRNA was transfected with the HDR 
oligo into a MEF cell line. 14 clones grew after a serial dilution of transfected cells. 
Because there were so few, we screened for CRISPR cutting directly by Sanger 
sequencing. 2 of 14 clones (14%) were edited. Both clones contained 3 mutant alleles, 
one in frame and two frameshift mutations. Aneuploidy is a common alteration in MEFs, 
which was confirmed in our cell line by karyotype analysis (data not shown, reference). 
Notably, there were no complete Naf1 knockouts. Western blotting using an antibody 
generated that is specific to mouse NAF1 (mNAF1) showed over an 80% decrease in 
NAF1 levels in both the mutant cell lines (Figure 3b, c). A similar percentage decrease 
was also seen in TR levels as measured in each by qRT-PCR. (Figure 3d). Overall, this 
evidence suggests that Naf1 could be an essential gene and that decreases in the levels of 
NAF1 levels result in proportional decreases in TR levels.  
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Figure 3. TR levels are decreased in mouse embryonic fibroblasts with decreased NAF1 levels. a. 
Schema of mouse wild-type Naf1 locus and CRISPR/Cas9 editing strategy to knockout Naf1. A sgRNA 
was designed to target exon 1 and introduce a nonsense mutation via homology directed recombination that 
would also alter the native SacII restriction site to a correctly edited NaeII restriction site that. Restriction 
digest of the target region PCR product with either enzyme followed by gel electrophoresis could be used 
to detect the presence of a wildtype or correctly edited allele. b. Immunoblot of lysate from human 
embryonic kidney (HEK) 293FT cells transfected with Myc-tagged Naf1 cDNA-containing plasmid at 
shown concentrations. Immunoblot for human NAF1 (hNAF1) and mouse NAF1 and Myc shows 
specificity of the murine NAF1 antibody. c. Immunoblot for NAF1 in CRISPR edited mouse embryonic 
fibroblasts. d. TR measured by qRT-PCR in Naf1+/+/+ (blue) MEFs compared to two different Naf1+/-/- 
mutant MEF cell lines (pink and purple) each containing one allele with an in frame mutation and two with 
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framseshift mutations. Levels were relative to hypoxanthine-guanine phosphoribosyltransferase (Hprt). For 
both Naf1+/+/+ versus Naf1+/-/- comparisons, P <0.001, n=3 technical replicates. 
 
NAF1 is an essential gene in mammals 
Studies in the MEF cell line point towards Naf1 being an essential gene in mammalian 
systems. To definitively address this observation, we decided to knockout Naf1 in a 
mouse model using the same CRISPR/Cas9 strategy used in the MEFs (Figure 3b). The 
sgRNA, Cas9 protein, and HDR oligo were injected into single cell zygotes of C57BL/6J 
mice, which were then implanted into surrogate mothers. 6 mice were screened for 
editing using restriction digest with SacII and NaeI enzymes. Cutting only occurred with  
the SacII enzyme suggesting there was no correct editing with the HDR oligo. 2 mice (2 
and 4) contained only wildtype alleles similar to the control wildtype MEFs, 1 mouse was 
heterozygous for a wildtype and mutant allele, and 3 mice had no cutting with either 
enzyme indicating two mutant alleles (Figure 4a). Sanger sequencing via TOPO cloning 
was carried out on pups containing two mutant alleles.  There were 6 mutant alleles 
among the 3 mice, and mouse 1 contained a predicted frameshift null mutation 
(c.320_641del322bp, p.G108Cfs*77) which was chosen to isolate and breed Naf1 null 
mice (Figure 4 a, b). This mouse was backcrossed to a wildtype mouse to generate a 
Naf1+/- heterozygous mouse which had half the levels of NAF1 compared to Naf1+/+  as 
measured by western blotting (Figure 4c). Naf1+/- heterozygous pups were then interbred 
across multiple generations to look for Naf1-/- mice, none of which were observed (>200 
screened, P < 0.001, Fisher’s exact test). Embryos were isolated as early as day E8.5-
E12.5 and genotyped, and again no Naf1-/- embryos were observed (n=32, P<0.01). These 
findings allowed us to conclude that Naf1 is an essential gene in mice. Additionally, TR-/- 
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mice are viable suggesting that the essential role in NAF1 lies beyond telomere 
homeostasis, and could involve RNA biogenesis. 
 
Figure 4. Naf1+/- mice were created using CRISPR/Cas9 editing. a. Genotyping using the SacII and 
NaeI restriction digest strategy (Figure 3a) of C57BL/6J mice created from injection of Cas9 protein, 
sgRNA targeting mouse Naf1 exon 1, and an oligo for homology directed recombination into single cell 
zygotes compared to control wildtype MEFs (n=6 mice). b. Schema of wild-type Naf1 locus and 
CRISPR/Cas9-induced 322-bp deletion (Δ322) in exon 1 and the amino acid sequence created by the 
frameshift mutation created (blue=wildtype, pink=mutant). c. Immunoblot for NAF1 in adult skin 
fibroblasts relative to Actin. 
 
NAF1 is necessary for telomerase RNA and noncoding RNA stability 
 18 
Given the proportional decrease in TR levels observed upon CRISPR knockdown of 
NAF1 levels in MEFs, we first measured TR levels in Naf1+/- mice to investigate whether 
heterozygous loss of NAF1 results in haploinsufficency for TR.  Naf1+/- mice had half the 
levels of TR compared to Naf1+/+ mice (61% by qRT-PCR and 51% by northern 
compared to controls, n=3, P  0.05). Notably, TR levels in Naf1+/- mice were also 
significantly increased compared to TR+/- mice whose levels were 44% by qRT-PCR and 
41% by northern compared to Naf1+/+ mice (Figure 5a,b,c). This difference between 
Naf1+/- and TR+/- mice is likely a reflection of heterogeneous TR levels among mice, 
among cell types, and within cells as has been shown in previous studies measuring TR 
levels in mouse testes and telomerase activity in various mouse tissues (54). However, 
this difference could also implicate NAF1 in TR 3’ end processing. A polyadenylated TR 
precursor was recently described that can accumulate when there is a processing defect 
involving proteins involved maturation or degradation including PARN (17); however, 
we measured polyadenylated levels of TR in Naf1+/- mice by priming RNA with 
oligo(dT) and normalizing TR levels measured by qRT-PCR to that of RNA primed by 
random hexamer which would measure total TR (mature+precursor) and found no 
increase in polyadenylated precursor TR (data not shown). This evidence points towards 
the biological variability as an explanation for the difference in TR levels between Naf1+/- 
mice and TR+/- mice. Given the significant decrease in TR levels and known role in 
H/ACA snoRNP complex, we were interested in the effect of decreased NAF1 levels on 
other RNA types. We measured 12 different H/ACA box, C/D box, long noncoding RNA 
(lncRNA), small nuclear RNA (snRNA), and mRNA levels by qRT-PCR in Naf1+/- mice 
and compared that to Naf1+/+ mice. Among 8 H/ACA RNAs, levels were on average 63% 
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(range 46 to 74%) of controls in Naf1+/- mice (n=3 to 8 mice), 3 were significantly 
decreased which  
Figure 5. RNA Levels in Naf1+/- mice. a. TR measured by qRT-PCR in Naf1+/+, Naf1+/-, mTR+/-, and 
mTR-/- mice (total spleen RNA, n = 3 mice per group) and normalized to hypoxanthine-guanine 
phosphoribosyltransferase (Hprt). b-c. Northern blot for mTR (mouse TR) normalized to 5.8S  (b) with 
quantifications of Naf1+/+(blue), Naf1+/- (pink), mTR+/- (purple), and mTR-/-  below (c).  d. H/ACA, C/D, 
splicing (snRNA), long noncoding (lnRNA) and messenger  (mRNA) RNA levels measured by qRT-PCR 
(n = 3 to 8 mice per group, total spleen RNA) and normalized to Hprt in Naf1+/+(blue), Naf1+/- (pink). Error 
bars represent SEM. **P < 0.01 and ***P < 0.001 (Student’s t test). 
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included included Snora64, Snora68, and Snora70 (n=8, P< 0.05). U14 and Snord17 C/D 
RNAs were significantly decreased at 43 and 41% of controls (n=3, P<0.05 and 0.01 
respectively). Both a lncRNA and snRNA had trending, but non-significant decreases in 
TR levels (66 and 71% decreases respectively) and GAPDH mRNA was not decreased 
(n=3) (Figure 5d). Overall, it appears that all non-coding RNAs had significant or 
trending decreases in RNA levels, including the lncRNA Rn7sl1 which is 299 base pairs 
and functions in the cytoplasm in association with the signal recognition particle 
ribonucleoprotein. This is surprising given that previous reports in yeast and HeLa cells 
suggest NAF1 is required specifically for H/ACA RNA stability (yeast and HeLa 
reports).  
 
Naf1+/- mice do not have detectable generational telomere shortening 
Haploinsufficiency of telomerase RNA in Naf1+/- mice raises the questions as to whether 
telomere shortening is detectable.  To measure telomere shortening we interbred Naf1+/- 
mice across 4 generations and measured telomere length by Flow-FISH (Figure 6a). No 
significant generational shortening was detected  across all four generations of Naf1+/- 
mice.  Specifically the difference in the geometric mean ratio between Naf1+/-G4 and 
Naf1+/+G1 mice was only 0.03 ± 0.02 (n=4 mice per generation, P=0.2647, Student’s t 
test, Figure 6b). The inability to detect shortening is not surprising given the long and 
heterogenous telomere length distribution in C57BL/6J mice. In contrast, CAST/EiJ mice 
have shorter and homogenous telomere length and significant shortening in TERT+/- mice 
can be detected even in 6 generations accompanied with decreasing testes and spleen 
weights (55). To corroborate the conclusions that the telomere length in the Naf1+/- 
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C57BL/6J mice was too long and heterogenous to have a clinical consequence and detect 
shortening across generations, the testes and spleens of each mouse were weighed prior to 
telomere length measurement, and neither testes nor spleen weights decreased across 
each generation of Naf1+/- mice (Figure 6c) 
 
Figure 6. Telomere length in Naf1+/- mice. a. Generational breeding strategy for generating Naf1+/-G1, 
Naf1+/-G2, Naf1+/-G3, and Naf1+/-G4 mice for telomere length measurement. b. Relative telomere length in 
lymphocytes isolated from spleens of Naf1+/+ G1 (blue), Naf1+/- G1 (pink), Naf1+/- G2 (purple), Naf1+/- G3 
(yellow), Naf1+/- G3 (green),  and mTR-/-G4 (orange) mice measured by measured by flow cytometry and 
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fluorescence in situ hybridization (flow-FISH) (n=3 mice per group). c. Relative weight of testes and 
spleens isolated from mice whose telomere lengths were measured in b (n=3 mice/ group). 
 
rRNA pseudouridylation in Naf1+/- mice is intact.  
 
H/ACAs function to guide targeted pseudouridylation at specific RNA uridine residues 
which is understood to be important for RNA integrity and function (21, 46). Over 133 
rRNA sites are predicted to be pseudouridylated, and given the decreases in H/ACA RNA 
levels in Naf1+/- mice we wanted to query modifications at rRNA sites using a recently 
developed high throughput, quantitative assay known as Pseudo-seq (46).We identified 
107 pseudouridines by homology to human rRNA sites, and of those, 82 sites met the 
quality cut off for analysis. The aggregate pseudouridine (Ψ) signal across all the Ψs 
detected in Naf1+/- mice was not significantly different from wild-type (96.7%, P=0.2, 
unpaired t-test, Figure 7a).  Examining each individual rRNA site revealed a similar 
Pseudo-seq signal and near equal correlation of Pseudo-seq signal at each of 82 sites in 
Naf1+/- mice compared to wildtype (R2=0.954, P<0.001) (Figure 7b). Additionally, 
because the rRNA sites analyzed by Pseudo-seq were identified based off conservation of 
mouse to human, we show targeted complementary binding of 6 mouse H/ACA RNAs at 
9 rRNA positions to verify that our rRNA sites analyzed were true H/ACA target sites 
(Figure 8a-i). Importantly, the levels of these H/ACA RNAs were measured by qRT-
PCR, and despite downward and significant decreases in RNA levels, pseudouridylation 





Figure 7. Pseudouridylation is intact in Naf1+/- mice. a. Alignment and Pseudo-seq strategy for 
identification of 82 pseudouridylation sites in mouse rRNA. b. Scatter plot of average Pseudo-seq signal 









Figure 8. Schema of mouse box H/ACA snoRNAs quantified showing the complementary guide 
sequence and the rRNA pseudouridine (Ψ) target site (red). a-i. The six snoRNA quantified in Fig 2.3d 
are shown here with their complementary sequence targeting 9 rRNA sites (shown in panels a-i). Each 
rRNA respective subunit is shown below. Eight of these rRNA sites were detected by Pseudo-seq as 
annotated in Table 1. In panels d, g, and i (designated by *), the murine RNA reference sequence was 
incomplete at the 5’ end, and sequence complementarity was derived from the genomic sequence based on 
build GRCm38/mm1. 
 
Naf1+/- mice do not have features of ribosomopathies.  
To further explore potential consequences of decreased H/ACA RNA levels, we wanted 
to clinically assess Naf1+/- mice. We hypothesized that if there were a clinical defect 
associated with the decreased levels, it could resemble ribosomapthies given the 
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importance of H/ACA RNA levels in modifying and maintaining ribosomal integrity. In 
humans, ribosomopathies are a hetergenous group of rare diseases with autosomal 
dominant or recessive inheritance caused by mutations in over 20 different 
ribonucleoproteins. Syndromes caused by these disorders commonly include craniofacial 
abnormalities and hematologic defects such as bone marrow failure, anemias, and cancer 
(Armistead, Triggs-Raine, FEBS Letters, 2014). Over 11 different types of mouse models 
currently exist for ribosomopathies which were created by engineering missense, null, or 
splicing mutations in a number of ribonucleoproteins. Clinical phenotypes of these mice 
are also heterogeneous and include but not limited to hematopoietic, skeletal, and 
craniofacial defects, and growth retardation (Terzian and Box, PLOS, 2015). We 
phenotyped first-generation Naf1+/- mice by performing necropsies including gross and 
histological tissue analysis of the head, abdomen (stomach, small intestine, colon, liver, 
spleen) and male reproductive organs (testes, epididymis, vas deferens, seminal vesicles, 
prostate, and penis) along with complete blood counts (white blood cells, neutrophils, 
lymphocytes, monocytes, red blood cells, hemoglobin, hematocrit, and platelets). No 
significant defects were observed (n=6 Naf1+/+, n=5 Naf1+/-). Overall, the intact 
pseudouridylation and clinically healthy phenotype of Naf1+/- mice suggests that the 
molecular defects associated with decreased H/ACA RNA levels are sufficient to 
compensate maintain cellular homeostasis within the mouse. Further, given that TR-/- 




Here we report findings that NAF1 is an essential gene in mice with only a telomere 
phenotype without defects in pseudouridylation in heterozygous state. Prior to these 
studies, pseudouridylation in mice secondary to defects in the dyskerin complex had only 
been studied in transgenic point-mutant catalase-inactive dyskerin embryonic stem cells, 
fibroblasts, and lymphocytes They report decreases in pseudouridylation in cell lines as 
measured by thin layer chromatography but with no analysis of systemic defects. (56, 57).  
Further, dyskerin is X-linked and male knockout mice are embryonic lethal and clinical 
assessment of mouse models was limited to a dyskerin hypomorph and low resolution 
pseudouridylation analysis of tissues and cells(58) (59). Naf1 mice here provide dan 
autosomal model of disease to cleanly study the consequences of 100% v 50% v 0% of 
dyskerin complex member NAF1. Dyskerin levels were intact in humans with 
heterozygous frameshift mutations in NAF1 and previous western blotting not shown here 
for dyskerin in Naf1 heterozygous null mice shows intact levels pointing to a NAF1 
specific defect in these mice. Pseudouridylation of rRNA as measured by high throughput 
sequencing is intact in Naf1+/- mice despite decreases in H/ACA RNAs as shown here and 
there is no clinical evidence of a ribosompathy as described in a multi-system phenotypic 
analysis. Whether or not pseudouridylation is defective as a consequence of dyskerin loss 
was not examined here, but our studies highlight H/ACA RNA levels cannot be a surrogate 
for function of pseudouridylation in other models. Futher, high-throughput 
pseudouridylation analysis through Pseudo-seq will be a standard for pseudouridylation 
compared to TLC in assessing these questions in the future. We would hypothesize that 
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some baseline unction of dyskerin will be sufficient to maintain adequate 
pseudouridylation in humans with dyskerin mutations as complete loss of 
pseudouridylation is lethal. Overall, Naf1+/- mice haploinsufficient for TR model patients 
with heterozygous loss of TR and point toward a purely telomeric effect in those 
individuals. 
 
Decreases in C/D along with H/ACA RNAs in Naf1+/- mice was surprising. These data 
could support a role for NAF1 in stabilization of non H/ACA small RNAs in mice through 
mechanisms not yet understood. One possibility to help explain this observation is that 
nascent pre-processed C/D RNAs could have H/ACA domains in the 3’ends that are 
removed in processing upon maturation. Alternatively mouse NAF1 in mice could identify 
C/D domains through a different mechanism. Mouse and human NAF1 proteins are only 
82% identical with poor conservation at the N terminus. Functional analysis at this protein 
region could shed light onto whether or not additional regulatory functions of NAF1 
beyond H/ACA RNA stability and targeting exist. C/D RNAs are involved in methylation 
of rRNA and methyl-seq of NAF1 mutant mice and MEF cell lines with 30% of NAF1 
could shed light as to wether C/D RNA function is compromised (21). However given our 
findings of intact pseudouridylation in heterozygous NAF1 mice, we would hypothesize 
methylation to also be intact. A side by side pseudo-seq and methyl-seq experiement of 
MEF cell lines could offer important clarity. Alternatively, our observations may reflect 
important differences in in vitro versus in vivo systems.  
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Finally, these data highlight the sensitivity of telomerase RNA dosage in cell lines in that 
just 50% loss of NAF1 in mice is sufficient to cause disrupt telomere homeostasis whereas 
50% loss of additional H/ACA is tolerated. This difference between TR and other H/ACAs 
is likely due to the low abundance of TR available to telomere elongation in the cell. Point 
mutations in human short telomere syndromes disrupting TR secondary structure are 
sufficient for destabilization of TR but even point mutations not disrupting base-pairing 
cause disease highlight the exquisite sensitivity of TR to perturbations normal homeostasis 
(60). Other sno and sca-H/ACAs are highly abundant on the order of magnitude of 1000 
fold high experession than TR such that loss of 50% may be tolerated. Pseudouridylation 
of rRNA is essential for life in one generation as we have shown here and cells may have 
adapted a large preserve to compensate when H/ACA levels are perturbed or compromised. 
Additionally, H/ACA RNAs have different regulatory mechanisms than TR being most 
commonly excised from introns of messenger RNAs whereas TR is a single exon gene 
with its own promoter (21). It is possible that loss of NAF1 has less effect on H/ACA 
function beyond stability given differences in regulatory function but we know loss of TR 
stability is sufficient for disease. Overall, telomerase RNA is tightly regulated and 
disruption of NAF1 is sufficient to cause telomere mediated disease in the context of 





Mice were housed in the Johns Hopkins University School of Medicine East Baltimore 
campus, and all procedures were approved by its Institutional Animal Care and Use 
Committee. All strains were maintained on the C57BL/6J background. TR+/− and TR−/− 
mice were generated and maintained as described (Blasco reference). 
 
Generation of Naf1 null mouse embryonic fibroblasts 
Targeting the Naf1 locus was performed using CRISPR/Cas9 (reference). A synthetic 
single-guide RNA (sgRNA) target sequence (5′-GGTCACCGGCCGGAACGCCG-3′) 
was designed to target exon 1 of Naf1(NC_000074.5) using the Optimized CRISPR 
Design tool (http://crispr.mit.edu/). This oligonucleotide was cloned into a pX459 
plasmid (gift from F. Zhang; Addgene, no. 48139) (reference). Prior to editing, 
karyotyping in Trf2Fl/Fl MEFs was performed showing aneuploidy (Celli reference). 
150,000 cells were plated in a 6-well dish one day prior to transfection and then 
transfected with 2 µg of pX459 plasmid using Lipofectamine 3000 (Invitrogen). After 24 
hours, cells were selected under 2 mg/mL of puromycin for 72 hours. Serial dilutions of 
selected cells were plated into 96-well plates and single colonies were grown out and 
screened for locus editing by Sanger sequencing, n=14 colonies (F- 5’ 
gctgcagacgctcaagttc 3’, R- 5’ aaaggaagcgggaactccta 3’).   
 
Generation of Naf1 null mice 
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Targeting the Naf1 locus was performed using the same CRISPR design described for 
mouse embryonic fibroblasts. However the pX459 was appended with a T7 promoter, 
and the sgRNA was in vitro transcribed and purified. The sgRNA and Cas9 (TriLink 
BioTechnologies) were co-injected into C57BL/6J zygotes (Johns Hopkins Transgenic 
Core). Pups (n = 6) were screened for locus editing by Sanger sequencing: 5′-
GCTGCAGACGCTCAAGTTC-3′ (forward) and 5′-AAAGGAAGCGGGAACTCCTA-
3′ (reverse) (838-bp wild-type allele). Mice were subsequently genotyped using this 
primer pair. 
 
Mouse skin fibroblast derivation and mouse phenotyping. Adult mouse skin 
fibroblasts were derived from wild-type, Naf1+/-, TR+/-, and TR-/- mice (7-18 weeks). 
Briefly, ear punches were washed in PBS containing penicillin streptomycin fungizone, 
minced in Hank’s Balanced Salt Solution (Gibco), and then digested with Collagenase B 
(Roche) and 0.25% Trypsin-EDTA (Gibco) for 20 minutes each at 37°C. The tissue was 
then washed and plated in Dulbecco’s Modified Eagle Medium (DMEM, Gibco) supplied 
with fetal bovine serum, glutamine, penicillin and streptomycin at standard 
concentrations. Timed matings were performed as previously described with vaginal 
plugs indicating E0.5 (9). E8.5-E12.5 embryos were dissected in PBS and DNA was 
extracted using the Gentra Purgene Mouse Tail kit (Qiagen). Phenotyping was performed 
on age- and sex matched (11-15 weeks, n=5/group) first generation Naf1+/- mice. 
Complete blood counts were measured using the ProCyte Hematology Analyzer (IDEXX 
Laboratories). Necropsy and tissue histology analyses were performed in a blinded study 
by a veterinary pathologist and included brain, liver, gastrointestinal tract, spleen, and 
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testes gross and microscopic analyses. 
 
Naf1 antibody generation. A polyclonal rabbit antibody against mouse Naf1 (Naf1 394) 
was generated using a synthetic peptide containing amino acids 394-408 
(NP_001157036.1) with the addition of an N-terminal cysteine (C-
QDRGSDASWKNDQE) (ProSci) as described (70). Antibody specificity was verified by 
plasmid transfection of Myc-tagged Naf1 (NM_001163564.1) in HEK-293FT (followed 
by immunoblotting using Myc and Naf1 394 antibodies. 
 
Immunoblotting studies 
Immunoblotting was performed as described (60). Briefly, cultured cells were lysed using 
radioimmunoprecipitation assay buffer supplemented with a protease inhibitor cocktail 
(Roche). Proteins were resolved with SDS–polyacrylamide gel electrophoresis, and after 
transfer to a nitrocellulose membrane were blocked in Odyssey blocking buffer (LI-
COR). The following primary antibodies were used: mouse Naf1 (rabbit, Naf1 394, 
1:250; Prosci) and actin loading control (mouse, ab8226, 1:2000; Abcam). Blots were 
visualized visualized by horseradish peroxidase– linked antibody (rabbit, 7074 and 
mouse, 7076 1:10,000; Cell Signaling Technology) and enhanced chemiluminescent 
substrate (Thermo Scientific).  
 
TR qRT-PCR 
Total RNA was extracted with the RNeasy Mini Kit (Qiagen) as recommended except 
that deoxyribonuclease digestion was performed using twice the volume and for an 
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extended period of 1 hour. Random hexamer-primed cDNA was synthesized using the 
SuperScript III Reverse Transcriptase kit (Invitrogen). Quantitative PCR of mTR was 
carried out as described (reference), respectively. Minor modifications included using 
freeze-thaw cycles to lyse cell pellets in lysis buffer and homogenization of total mouse 
spleens using the Bullet Blender (Next Advance). For each experiment, the side by-side 
comparisons were made on simultaneously prepared cDNA. 
 
TR northern blot. Northern blot was performed as previously outlined (62) with minor 
modifications. Briefly, 25 μg of total RNA was resolved on a 1.5% agarose-formaldehyde 
gel. RNA was vacuum transferred to HybondTM-N+ (GE Healthcare, Amersham) nylon 
membrane in 10x SSC for 1 hour followed by UV crosslinking. Pre-hybridization was 
performed in Church buffer [500 mM sodium phosphate (pH 7.2), 1 mM EDTA, 1% 
BSA, 7% SDS] for 1 h at 65oC. DNA probes were labeled with [α-32P] dCTP by random 
priming. Membranes were hybridized with mTR and 5.8S probes overnight in Church 
buffer at 65oC. The membrane was washed with two quick rinses at 65oC in 2x SSC 
solution, followed by five rinses in 2x SSC and 0.1% SDS, at room temperature (5 
minutes each), and then for 30 minutes in 0.1x SSC and 0.1% SDS. Blots were exposed 
to a phosphor screen and visualized on Storm 825 system (GE Healthcare). 
 The mTR probe, which included the 397 bp mTR sequence plus 142 bp of flanking 
sequences from the genomic locus, was excised from plasmid DNA (Bluescript KS+ 
JHU1145, gift from Carol Greider, Johns Hopkins University) by Not1/Sal1 restriction 
digest (New England BioLabs) and gel-purified. The human and mouse 5.8S sequences 
are 100% identical and we used the same probe amplified from mouse gDNA to detect 
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5.8S as a loading control for mTR. The probe was generated using this primer pair: 
5’-GACTCTTAGCGGTGGATCAC-3’ (forward), 5’ GACGCTCAGACAGGCGTAG-3’ 
(reverse) (152 bp). 
 
H/ACA RNA identification and quantification by qRT-PCR. We quantified seven 
mouse H/ACA RNAs and identified them based on ≥ 80% sequence identity with their 
human homologs. Sequence identity between mouse and human RNAs were identified 
using  BLASTn using these mouse sequences: Snora62 (NR_002902.2), Snora63 
(ENSMUST00000082448), Snora64 (NR_002897.1), Snora65 (NR_002898.2), Snora69 
(NR_002900.1), Snora70 (NR_002899.1), and Scarna13 (NR_028576.1). Target sites in 
mouse rRNAs [(5.8S (NR_003280.2), 18S (NR_003278.3), and 28S (NR_003279.1)] 
were extrapolated based on the known target sites in human rRNA using the 
snoRNABase Version 3 Database (71). They were then verified manually by the presence 
of a complementary and ACA sequence. For qRT-PCR analysis, standards were 
generated using plasmid DNA containing each RNA sequence. These were cloned from 
mouse total spleen cDNA using random hexamer priming. The details of the qRT-PCR 
procedure were as described for mTR. Primer sequences and PCR conditions are 
available upon request. 
 
Telomere length measurement. Telomere length was measured by flow-FISH (57). The 
flow-FISH method includes extensive controls, including MESF (molecules of equivalent 
soluble fluorochrome) beads and cow thymocyte internal control (57). Telomere length 
data were plotted as the relative geometric mean intensity of Naf1+/+G1 mice.  
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Pseudo-Seq library preparation. Pseudoridine site quantification was performed on 
total RNA extracted from mouse spleens by Pseudo-Seq as previously described with 
minor modifications (39). The total and site-specific pseudouridine quantification was 
performed on the same samples. Briefly, libraries were prepared by fragmenting 5 μg 
total RNA in 10 mM ZnOAc at 60ºC for 20 minutes, followed by CMC modification and 
reversal. RNA fragments (60-80 nt) were gel purified, and prepared for reverse 
transcription (RT) by ligation of a pre-adenylated adapter to the 3′ ends. Following RT, 
truncated cDNAs were gel purified, circularized with circLigase (Epicentre) at 60ºC for 
6h and PCR amplified. Libraries were sequenced on an Illumina HiSeq2000.  
 
Identification of mouse rRNA pseudouridines and pseudouridine quantification. 
Mouse rRNA pseudouridines were identified in two steps. First, conservation of 
modification between human and mouse was assumed. The positions in mouse rRNAs 
corresponding to known human rRNA pseudouridines (39, 71) were determined by 
aligning human (18S: X03205, 28S: U13369 nts 7935-12969, 5.8S: U13369 nts 6623-
6779) and mouse rRNAs (18S: NR_003278.3, 28S: NR_003279.1, 5.8S: NR_003280.2) 
with Clustal Omega (72). Second, additional pseudouridylation events in mouse rRNA 
were identified by analysis of Pseudo-seq libraries with the following peak calling 
parameters: a peak cutoff of 1.0, and reproducibility in >80% of libraries. Reads were 
processed and mapped to the mm10 transcriptome (UCSC, downloaded May 13, 2015). 
Peak values were calculated as follows: For a given Ψ, the reads whose 5’ ends map to 
each position in a 51 nt window centered at the Ψ were normalized to the total number of 
reads in the window. This normalization was performed for both the +CMC and –CMC 
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libraries. The normalized reads at each position in the window in the –CMC library were 
subtracted from the normalized reads at that position in the +CMC library. Finally, each 
position in the +CMC and –CMC calculation was scaled by the window size. Only those 
sites with a peak value of greater than 1.0 in 6 of 7 +/- CMC library pairs were 
considered for further analysis. A total of 107 Ψ sites were identified in this analysis; 
these are listed in Table 1 with the detected Ψ sites (n=82) annotated. The variance in 
measurement of site-specific pseurouridine ratios was compared within a given genotype, 
Naf1+/+ (n=4 assayed) and Naf1+/- (n=3 mice assayed), and showed an intra-group ratio 
range of 2% to 10%. The raw Pseudo-seq data were deposited in NCBI’s GEO database 
(submission ID 17772667, Accession ID GSE78063). 
 
Statistical analyses 
Statistical comparisons were made with GraphPad Prism software, and all P values are 
two-sided. Student’s t test was used for comparison of means, and P values less than 0.05 
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Telomerase is a specialized ribonucleoprotein that synthesizes telomere repeats (1, 20). It 
has two core components: TERT, the telomerase reverse transcriptase, and TR (also 
known as TERC), the telomerase RNA component, which provides the template for 
telomere addition (2, 31, 61). In humans, mutant telomerase genes have their most 
common manifestation in a degenerative age-related disease known as idiopathic 
pulmonary fibrosis (IPF) (9, 62). Mutant telomerase genes are the most common cause of 
autosomal dominant IPF, and a subset of IPF patients show systemic features of a short 
telomere syndrome including bone marrow failure (63). Among the IPF families with 
identifiable mutations, half carry mutations in TERT or TR (9, 64). The other half carry 
mutations in one of five other telomere maintenance genes, RTEL1, PARN, NAF1, 
TINF2, and DKC1 (16, 18, 65-67). Four of the seven heretofore identified telomere 
maintenance genes linked to familial IPF affect TR itself, or its de-adenylation, 
trafficking or biogenesis as is the case for PARN, NAF1 and DKC1, respectively (17, 18, 
68).Fifty to 70% of familial IPF patients have no identifiable cause and, within this 
subset, there are individuals with obvious features of a short telomere syndrome and 
unexplained low TR levels (18). One hurdle to gene discovery in these families is that 
candidate genes have been exhausted. Moreover, combining gene discovery efforts across 
families is problematic because there is extreme locus heterogeneity with each of the 
recently discovered genes accounting for only 1-3% of uncharacterized cases (16, 18). 
There is also the additional challenge of assigning affected status clinically since IPF is 
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generally a disease of older adults and, once diagnosed, it usually has a rapidly 
progressive course.   
 
Here, we used molecular and clinical phenotyping with genome wide linkage analysis to 
identify a novel regulator of TR maturation that is mutated in familial pulmonary fibrosis.  
Human TR has its own promoter and is transcribed by RNA polymerase II. Vertebrate 
TR shares a 3’end box H/ACA motif with a subset of other non-coding RNAs, but 
relative to these and other mRNAs, it has very low abundance (18, 47, 69). This scarcity 
makes telomere length maintenance highly vulnerable to even minor reductions in TR 
dosage and function (3, 4). In human families, even hypomorphic TR mutations cause 
autosomal dominant IPF with genetic anticipation (9, 70). The regulation of vertebrate 
TR transcription, processing and assembly with TERT remain incompletely understood 
in part because TR sequence is divergent and organisms have adapted distinct 
mechanisms for post-transcriptional processing and 3’-end maturation (69) (71). For 
example, T. thermophila TR is transcribed by RNA polymerase III that relies on runs of 
Ts for transcriptional termination (2). S. cerevisiae TR (known as TLC1) relies on a 
3’end Sm-binding complex in addition to the Nrd1-Nab3-Sen1 complex for proper 3’ end 
processing by the RNA exosome (24, 25). S. pombe on the other hand uses a modified 
spliceosome-dependent cleavage mechanism as the initial 3’end processing step (25). 
Vertebrate TR is transcribed as a longer transcript and while its processing has been 
suggested to be linked to the RNA exosome (30, 40), the determinant components for its 
maturation are not known.  Here, we report mutant ZCCHC8, the zinc finger CCHC-type 
domain containing 8 protein, as a cause of TR insufficiency and familial IPF.  ZCCHC8 
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was identified as a component of the Nuclear Exosome Targeting Complex (NEXT) (37), 
which has been implicated in targeting a subset of RNAs to the nuclear RNA exosome, 
but has not been linked to TR maturation.  We show that ZCCHC8 is required for nascent 
TR processing.  
 
RESULTS 
Genome wide linkage analysis identifies mutant ZCCHC8 in a family with autosomal 
dominant pulmonary fibrosis 
We identified an adult with IPF who showed classic short telomere syndrome features 
including bone marrow failure.  His family history was consistent with autosomal dominant 
pulmonary fibrosis (Figure 9A).  He had low TR levels in lymphoblastoid cell lines by 
qRT-PCR, similar to a patient with mutant DKC1 (Figure 9B).  Whole genome sequencing 
identified ~3600 rare variants that deviated from the reference genome, but none of them 
fell in known TR-related genes.  To identify the disease-causing variant, we recruited 13 
of his relatives, but found no clinically affected individuals (Figure 9A).  This led us to 
assess their preclinical status by measuring TR levels and we found the proband’s two sons 
similarly had 50% lower TR levels compared to unrelated healthy controls as well as 
marry-ins from the same family (Figure 9B). The other remaining relatives had intact TR 
levels (Figure 9B).  Telomere length by flow cytometry and FISH (flowFISH) confirmed 
the two children were pre-clinically affected since they both had abnormally short telomere 
length, well below the first age-adjusted percentile, and had shorter telomere length than 
the proband (Figure 9C).  This finding is similar to the successive telomere shortening seen 
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in families with TERT and TR mutations which underlies telomere-mediated genetic 
anticipation (63, 70, 72). The molecular studies supported assigning pre-clinical affected 
status to the two pre-symptomatic individuals, in addition to  
 
 
Figure 9. Linkage analysis identifies the ZCCHC8 locus containing a novel mutation that segregates 
with familial pulmonary fibrosis and telomerase RNA (TR) insufficiency. A. Pedigree with proband 
(designated by arrow) and relatives who had pulmonary fibrosis are indicated by the shaded symbols (Key). 
The ‘?’ refers to individuals whose clinical status was uncertain at the time of clinical assessment and the 
individuals shaded in gray had an unknown cause of death.  *Refers to individuals for whom DNA was 
available. B. TR levels measured by quantitative real time PCR (qRT-PCR) in lymphoblastoid cell lines 
(LCLs). Arrow refers to proband (red dot) and pedigree identifiers refer to A (proband’s sons).  TR levels 
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from a DKC1 mutation carrier is a positive control. The data represent a mean of three experiments, each 
from independent RNA isolations. C. Telogram shows age-adjusted lymphocyte telomere length by flow 
cytometry and fluorescence in situ hybridization (flowFISH) in the proband (arrow) and his family. 
Pedigree designations are as in A.  The telogram is based on clinically validated dataset from 192 controls. 
D. Phenotype assignments as shown in key that were used in genome wide linkage analysis based on the 
presence of pulmonary fibrosis as well as TR levels (B) and telomere length measurement (C). The 
ZCCHC8 single nucleotide variant for the P186 change is also shown below each pedigree symbol and 
italicized genotypes refer to obligate carriers. E. Log of the odds ratio score across the autosomal 
chromosomes calculated from 15 individuals identified by * in (A).  The linkage peak on chromosome 12 
is denoted by the arrow.  F. Novel protein coding mutation identified p.P186L falls in an unstructured 
domain of ZCCHC8 with alignment across eight vertebrate species shown. The darker shading denotes 
more conserved identity conserved residue identity. CCHC refers to Zinc-knuckle domain; PSP refers to 
proline-rich domain. 
 
the proband, and the remaining family members, who had intact TR levels, were designated 
as unaffected (Figure 9D).  Using these assignments, we performed genome wide linkage 
analysis and identified a single 17.3 Mb linkage peak on chromosome 12 (1073260-
1246120) which had a maximum log of the odds ratio (LOD) score of 2.99 (Figure 9E).  
Within this interval, there were three rare coding and no rare splice-altering variants.  Only 
one of these variants was novel; it fell in an RNA metabolism gene, ZCCHC8. The variant 
predicted a missense mutation c.C557T, p.P186L and was absent in more than 140,000 
individuals (genome Aggregation Database, Exome Variant Server, 1000 Genomes, 
dbSNP) (Figure 9F).  Within the family, the ZCCHC8P186L variant segregated with the 
pulmonary fibrosis and low TR-short telomere phenotypes, including in obligate carriers 
(Figure 9D).  P186 falls in a highly conserved but unstructured domain of ZCCHC8 (Figure 
9F).  We screened 42 genetically uncharacterized families with pulmonary fibrosis and 
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other short telomere syndrome phenotypes by targeted sequencing of ZCCHC8, but we did 
not identify additional variants, suggesting these mutations are rare in uncharacterized 
cases (1 of 43, 2%). This finding is consistent with the locus heterogeneity of short telomere 
syndromes.   
 
ZCCHC8P186L is a loss-of-function mutation 
To characterize the significance of ZCCHC8P186L, we tested whether it affected protein 
integrity and found mutation carriers had nearly 50% lower ZCCHC8 protein levels in 
lymphoblastoid cells compared to controls and non-carriers in the same family (P=0.038, 
Mann-Whitney U-test, Figure 10A and antibody validation not shown).  The lower 
ZCCHC8 protein levels were also seen in proband’s primary skin fibroblasts (Figure 10B).  
Notably, the decrease was specific to ZCCHC8 as we saw no significant change in the 
levels of the other two NEXT complex proteins, RBM7 and SKIV2L2 (Figure 10B and 
antibody validation not shown). We tested whether the low protein expression was due to 
decreased mRNA or protein stability and found that ZCCHC8 mRNA levels were intact in 
mutation carriers (mean 1.6-fold ± 0.2 s.e.m relative to controls, Figure 10C). Moreover, 
the mutation was detected in the mRNA (Figure 10D), further indicating that P186L 
compromised ZCCHC8 protein levels.  To test this directly, we quantified the stability of 
transfected Myc-tagged wild-type and mutant ZCCHC8 and found p.P186L mutant levels 
were lower, supporting the conclusion that this mutation disrupts protein stability (Figure 
10E).  We next tested whether ZCCHC8 loss affects TR levels. We generated HeLa cells 
that stably express an shRNA against ZCCHC8 and found that TR levels were significantly 
reduced, similar to NAF1 knockdown (Figure 10F-H).  The decrease in total TR levels was 
 43 
detected by qRT-PCR as well as northern blot (Figure 10G-H and TR northern specificity 
validated and not shown).  These data indicated that ZCCHC8P186L is a loss-of-function 
mutation and that ZCCHC8 loss is sufficient to cause TR insufficiency.   
 
Figure 10. Pulmonary fibrosis-associated mutation affects ZCCHC8 stability.  A. Immunoblot of 
endogenous ZCCHC8 levels in lymphoblastoid cell lines (LCLs) from healthy controls (C1 and C2), 
unaffected relatives and mutation carriers as indicated. Result replicated in two other blots.  Pedigree 
identifiers refer to Figure 1A. B. Immunoblot showing ZCCHC8, SKIV2L2 and RBM7 levels in primary 
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and ZCCHC8 p.P186L mutation carriers (n=3). D. Chromatogram showing ZCCHC8 p.P186L mutation is 
detectable in mRNA from LCLs. E. Immunoblot of transfected Myc-tagged (into 293FT cells) and 
endogenous ZCCHC8 showing the P186L mutation is less stable. F. Immunoblot showing efficacy of 
shRNA knockdown of Luciferase (Luc), ZCCHC8 and NAF1 in HeLa cells on protein levels. G. Total TR 
levels measured by qRT-PCR after knockdown. Mean is from 3 independent knockdowns.  H. Northern 
blot shows low TR levels after stable knockdown of ZCCHC8 and NAF1. Quantification is shown below 
each of the gels and each experiment was replicated at least twice where not noted. For C and G, the mean 
± SEM is shown. **P<0.01 and ***P<0.001 (Student’s t-test, two-sided). 
 
ZCCHC8 is required for nascent TR 3’-end processing and for telomerase function 
 
To test the consequences of ZCCHC8 loss on TR integrity and telomerase function, we 
generated ZCCHC8 null HCT116 pseudodiploid cells by CRISPR/Cas9 editing (Figure 
11A-B).  The NEXT complex is thought to target a subset of nascent RNAs for 3’end 
processing by the nuclear RNA exosome (37) and we hypothesized that TR’s 3’ends may 
be misprocessed in mutant cells. We used a next generation sequencing approach that 
characterized TR’s 3’ends by Rapid Amplification of cDNA Ends followed by sequencing 
(3’RACE-seq) (Figure 11C).  We found that compared to isogenic controls, ZCCHC8-/- 
cells had decreased mature TR fraction (451 nt long) and increase in 3’extended TRs 
(Figure 11D).  The longer forms included adenylated mature TR as well as extended forms 
which mapped to the genomic locus beyond the annotated mature TR 3’-end, consistent 
with their being nascent precursors (Figure 11D).  We categorized these extensions based 
on the bioinformatic tools we used as short (<15 nt beyond the mature 3’end) and long 
(>15 nt), and we found ZCCHC8-/- cells had increased levels in both of these categories.  
We directly quantified the longer TR forms by qRT-PCR and found 4- to 10-fold higher 
levels of these TRs which extended +20, +51, and as far as +784 nucleotides beyond the 
mature TR 3’end (Figure 11E).  Total TR levels were also low in ZCCHC8-/- cells by 
northern blot (mean 79%, P=0.038, Student’s t-test, Figure 11F-G.  TR levels measured by 
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northern blot may however over-estimate the fraction of functional TR since a significant 
of TRs in ZCCHC8-/- cells were 3’extended.  We therefore directly measured telomerase 
enzyme activity using the telomere repeat amplification protocol (TRAP) assay, and found 
that, similar to NAF1 mutant cells (18), ZCCHC8-/- cells had decreased TRAP activity 
(mean 52% of isogenic ZCCHC8+/+ cells, P=0.001, Student’s t-test, Figure 11H-I).  These 
data showed that ZCCHC8 is required for TR 3’end processing and for telomerase enzyme 
function. 
 
To test the clinical relevance of these observations, we performed 3’RACE-seq on the 
proband’s primary fibroblasts and found they had a similar TR length distribution as 
ZCCHC8-/- cell lines (Figure 11J).  There was a relative decrease in mature TR and, 
conversely, an increase in the TR fraction with short (<15 nt) and long (>15 nt) extensions 
beyond the mature 3’end (Figure 11J).  Quantification by RT-PCR also confirmed these 
extensions at +20, +51 and +784 nucleotides beyond the mature TR 3’end (Figure 11K).  
We, however, found heterogeneity in the stability of these longer TR forms across cell 
types since we could not amplify them readily from Epstein-Barr virus-transformed 
lymphoblastoid cells, consistent with data suggesting herpes viruses can interfere with 




Figure 11. Pulmonary fibrosis-associated mutation affects ZCCHC8 stability.  A. Chromatogram 
showing compound heterozygous frameshift (fs) mutations generated using CRISPR/Cas9 in HCT116 
pseudodiploid cell lines. B. Immunoblot for ZCCHC8 in HCT116-edited cells. C. Schema summarizing TR 
3’ Rapid Amplification of cDNA Ends sequencing (3’RACE-seq) method. TR 3’ends were generally 
divided into mature (451 bp) and extended (>451 bp) where extensions are denoted by gray N’s.  D. 
Summary of TR 3’RACE-seq fractions in ZCCHC8+/+ and ZCCHC8-/- HCT116 cells. The color-coded key 
shows the different categories of TR forms including adenylated and genomically-extended forms that are 
adenylated and long extended forms that are >465 nucleotides.  Data reflect mean of 3 independent 
3’RACE-seq analyses each from a different RNA isolation.  ZCCHC8+/+ cells were isogenic having 
undergone selection.  E. qRT-PCR of extended TR forms beyond the 451 mature end (>20, >51, >784 
nucleotides).  Data reflect mean values from three independent RNA isolations.  F. Northern blot for TR of 
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independent RNA isolations. H. Telomerase activity measured by Telomere Repeat Amplification Protocol 
(TRAP) assay in ZCCHC8+/+, ZCCHC8-/-, and NAF1S329/S329 HCT116 cell extracts. Activity was quantified 
in serially diluted extracts (1, 1/5, 1/25, 1/125) against a PCR-amplified internal control (IC). An RNAse 
treated wild-type extract and no template PCR reaction are negative controls.  I. Mean TRAP activity of 
1/5x diluted extracts from 3 independent TRAP assays each from a different cell lysate. J. Summary of 
3’RACE-seq of TR forms from control and proband primary skin fibroblasts as in (D).  K. Mean qRT-PCR 
values of extended TR forms in primary skin fibroblasts as in (E) (n=3 technical replicates).  Data are 
expressed as means ±SEM. *P < 0.05 and **P < 0.01 (Student’s t- test, two-sided). 
 
ZCCHC8 associates with TR precursors and nascent TR accumulation is rescued by 
a catalytic RNA exosome component 
Our genetic data indicated that ZCCHC8 is required for 3’end processing of TR. To test if 
ZCCHC8 associates with TR, we performed RNA immunoprecipitation (IP) with Myc-
tagged ZCCHC8 in 293FT cells (Figure 12A) and found TR was enriched in the 
immunoprecipitated fraction (Figure 12B).  We considered whether this amplification may 
be secondary to an association with the dyskerin complex, but we could not co-
immunoprecipitate dyskerin or NAF1 with Myc-ZCCHC8 (Figure 12C).  We then 
examined whether ZCCHC8 interacts with TR precursors by performing TR-specific 
3’RACE-seq of ZCCHC8-immunoprecipitated RNA. We found an enrichment of longer 
TR forms containing genomically-encoded 3’ends in the ZCCHC8-bound RNA IP fraction 
(Figure 12D). The majority of the extensions were shorter than 15 nt (Figure 10D). We 
directly tested whether the accumulation of TR precursors may be rescued by forced 
expression of DIS3, a 3’>5’ exoribonuclease of the RNA exosome (Figure 12E).  
Exogenous expression of ZCCHC8 rescued the accumulation of nascent TR in HCT116 
ZCCHC8-/- cells, as expected for an on-target effect.  Over-expression of DIS3 also had a 
similar effect in reducing these extended TR forms (Figure 12F). These data supported that 
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nascent TR accumulation in ZCCHC8 deficient cells is linked to inadequate nuclear RNA 
exosome targeting likely through DIS3. 
Figure 12. ZCCHC8 immunoprecipitates TR precursors with genomically encoded 3’ends. A. 
Immunoblot showing input (I) and immunoprecipitated (IP) Myc-tagged ZCCHC8 plasmid transfected at 
two concentrations into 293FT and harvested at 48h. The lower most panel is an over-exposed blot to show 
the relative levels of tagged ZCCHC8 relative to endogenous.  B. Amplified TR from I and IP fractions 
using primers within the mature TR sequence. C.  Western blot of IP Myc-tagged ZCCHC8 shows no 
detectable dyskerin or NAF1 co-IP. D. Deconvoluted TR 3’RACE-seq data showing enrichment of 
genomically encoded TR precursors in the Myc-ZCCHC8 fraction compared to input.  The genomic TR 
locus with the 451 mature 3’-end is annotated in the left upper corner.  In the color-coded key of the TR 
species, Misc refers to non-genomic, non-templated nucleotides other than ‘A.’ E.  Western blot showing 
transfection of Myc-tagged ZCCHC8 and DIS3 plasmids into CRISPR/Cas9 edited HCT116 cells (Figure 
3A). E. qRT-PCR of nascent TR that is >51 nucleotides extended beyond the 3’ mature TR end with 
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Using linkage analysis in a family with autosomal dominant pulmonary fibrosis, we 
identified a novel regulator of telomere maintenance and TR 3’end processing.  We show 
ZCCHC8 is required for TR function by mediating its 3’end maturation through targeting 
to the nuclear RNA exosome. Our data are notable, since we show that, while ZCCHC8 is 
required for the processing of other RNAs, heterozygous loss is tolerated and, in humans, 
selectively manifests as a short telomere phenotype including pulmonary fibrosis. In yeast, 
the most common functional category of telomere length regulators is RNA processing 
genes which account for nearly one-third of all hits (12-14).  Our data support the short 
telomere phenotype, especially familial pulmonary fibrosis, being enriched for mutant 
regulators of TR integrity.   
 
The NEXT complex nor the RNA exosome has not been previously implicated in 
telomerase RNA maturation. Nascent telomerase RNA has been shown to accumulate upon 
knockdown of various core RNA exosome components and RBM7 but only been 
implicated as a step in degradation. Further those studies were limited to aneuploid cancer 
cell lines where RNA turnover and nascent telomerase RNA accumulation may vary from 
those of primary human cells and mask an underlying defect in a very low abundant RNA 
(30, 40). Specifically ZCCHC8 has not been shown to affect telomerase RNA processing 
either in maturation or degradation in transient siRNA knockdown HeLa studies (40).  Here 
we show upon stable knockdown of telomerase RNA in multiple independent transduction 
experiments across multiple assays, both qRT-PCR and northern blot analysis, total TR is 
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significantly decreased. Further, nascent transcripts accumulate but regardless, telomerase 
activity is compromised despite these accumulations. This is similar to findings when loss 
or mutation of the polyadenylase PARN results in accumulation of nascent TR with 
compromised telomerase homeostasis in patients and cell lines (17, 30). Given this and our 
findings, we would hypothesize 3’ extended transcripts to be nonfunctional. Future in vitro 
direct telomerase assay with extended transcripts of different lengths can definitively 
answer this question and be an important step in solidifying the functional characteristics 
and processing of nascent TR.  
 
The implication of the NEXT complex and RNA exosome expands our understanding of 
TR 3’-endprocessing. Prior to these discoveries presented here defective TR 3’ end 
processing in PARN mutant patient cells resulting in accumulation of short, polyadenylated 
TR transcripts caused a short telomere phenotype in heterozygous and biallelic families 
(16, 17). These findings implicated deadenylation into the maturation pathway of TR; 
however, the question of how nascent TR is trimmed to the most common “mature” 451 
bp form has remained elusive. Longer TR forms have been reported and detected in cell 
lines (30)but how or whether these longer nascent TR forms are trimmed to the shorter 
mature forms was unclear. Here we propose a model by which nascent TR is transcribed 
by RNA polymerase II to extended TR forms that are subsequently trimmed and processed 
back at the 3’end to functional 451 bp form. Nascent TR forms are likely polyadenylated 
as are other RNA pol II transcripts and targeted either to maturation or degradation. We 
propose that ZCCHC8 via the NEXT complex targets long, genomically extended forms 
towards maturation. This likely involves additional processing by PARN to remove 
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polyadenylated tails. Failure to do so results in accumulation of both genomically extended 
and polyadenyalted nascent TR forms that are subsequently targeted to degradation. 
Without proper trimming and 3’-end processing by ZCCHC8 and the NEXT complex, 
mature TR forms are not produced and TR is unable to serve as a template for telomere 
elongation in its immature forms.  
METHODS 
Subjects and study approval. Patients were recruited from 2007-2017 as part of the Johns 
Hopkins Telomere Syndrome Registry as previously described (74).  The study was 
approved by the Johns Hopkins Medicine Institutional Review Board and all the subjects 
gave written informed consent.  The proband was identified in a screen for individuals who 
had low TR levels in lymphoblastoid cell lines (LCLs) by qRT-PCR as previously 
described (18).  LCLs were generated by Epstein Barr virus transduction (75), and primary 
skin fibroblasts from the index case were derived from a skin punch biopsy using standard 
methods. Control skin fibroblasts were purchased from ATCC (BJ, CRL-2522).  The 
screen of 42 patients for mutant ZCCHC8 included genetically uncharacterized familial 
pulmonary fibrosis-emphysema probands (n=31) and patients with a classic short telomere 
syndrome phenotype and short telomere length as previously defined (n=11) (18). 
 
Telomere length measurement and DNA extraction.  Telomere length was measured on 
peripheral blood-derived cells by flow cytometry and fluorescence in situ hybridization 
(flowFISH) at the Johns Hopkins Pathology Laboratories as described (74, 76). Genomic 
DNA was extracted from fresh blood or PBMCs using the Gentra Puregene Kit B (Qiagen) 
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and from formalin-fixed paraffin embedded (FFPE) using the FFPE Tissue DNA Isolation 
Kit (MO BIO Laboratories). 
 
Quantitative Real Time-PCR (qRT-PCR) for TR. RNA levels were measured using the 
SYBR Green qRT-PCR method as previously described (18). Briefly, RNA was isolated 
(RNeasy, Qiagen) and reverse transcribed using random hexamer primers and Superscript 
III (Invitrogen). Within any given experiment, RNA isolation and cDNA reverse 
transcription were side-by-side for all the samples.  TR levels were normalized to ARF3 
(human). Primers for quantifying hTR extensions were from (30, 40). 
 
Whole genome sequencing. Whole genome sequencing was performed on blood-derived 
DNA (Macrogen) using a HiSeq X platform (Illumina).  Variants were called and aligned 
to GRCh37 reference genome using the Isaac variant caller (v.2.0.13) and aligner 
(v.01.15.02.08).  The mean depth of coverage was 48X with 98% of the genome covered 
at 20X and 93% at 30X.  Annotation and filtering was performed using PhenoDB (77). 
Non-synonymous exonic and splice junctions were defined as rare if they were absent in 
dbSNP builds 129, 131 and 135, and also had minor allele frequency (MAF) less than 
0.0001 in 1000 genomes and the NHLBI GO Exome Sequencing Project (accessed June 
19, 2017 and updated January 6, 2019).   
 
Genome wide linkage analysis. To identify the disease gene, we genotyped a total of 14 
individuals using a SNP array (548K, Infinium HumanCoreExome-24v1-0, Johns Hopkins 
Genetic Center Resource Facility).  SNPs were ranked in 400 kb bins by quality metrics 
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based on call rates, position and tightness of the genotype cluster. The 6,710 high quality 
autosomal SNPs were then used in a singlepoint linkage analysis using MERLIN software 
(78).  Subjects were assigned ‘affected’ status if they had a short telomere syndrome 
phenotype such as IPF, were obligate carriers, or had low TR levels and abnormally short 
telomere length. We used an autosomal dominant model with prevalence of 0.0001, and 
penetrance of 1.0 and 0.0001 in carriers and non-carriers, respectively.   
 
ZCCHC8 multiple species alignment. Human ZCCHC8 (NP_060082) was aligned to the 
following vertebrate ZCCHC8 protein sequences (Canus familiaris: XP_005636220; Mus 
musculus: NP_081770; Bos taurus: NP_001192619; Gallus gallus: NP_001192619, 
Xenopus tropicalis: NP_001135573; Oryzias latipes: XP_004072626; and Danio rerio: 
NP_001077287) within Jalview (version 2.10.2b2) using Clustal Omega (79). 
 
Targeted sequencing of ZCCHC8. The heterozygous ZCCHC8 P186L variant was verified 
using Sanger sequencing of the 102 bp magnetic bead purified PCR product (AMPure XP, 
Beckman Coulter Life Sciences) using primers available upon request.  To screen for 
ZCCHC8 mutations in short telomere syndrome patients, we sequenced gDNA for the 
coding sequence and exon-intron junctions on a customized targeted nextgen sequencing 
panel (Truseq, Illumina) as previously (n=21 cases) (42). The mean depth of coverage was 
50X.  For remaining cases (n=21), we Sanger sequenced the ZCCHC8 cDNA derived from 
LCLs bi-directionally (primers available upon request).   
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Western blots. Total protein was isolated from cells in RIPA buffer (Cell Signaling 
Technology) with cOmplete Mini protease inhibitor (Sigma-Aldrich) and lysates were 
quantified using Pierce BCA Protein Assay Kit (Thermo Fisher Scientific). Using the 
NuPAGE SDS-PAGE gel system, protein (10-20µg) was run on 10% Bis-Tris gels with 
MOPS-SDS running buffer at 150V and transferred to a PVDF membrane by wet transfer 
using XCell SureLock Mini-Cell Elecrophoresis System or by the iBlot 2 Dry Blotting 
System at 30V (Thermo Fisher Scientific). Immunoblotting was performed using the LI-
COR system as previously (18). Membranes were blocked for 1h to overnight prior to 
antibody staining. The following antibodies were used with clone identifiers listed for the 
two monoclonal antibodies (Actin and Myc): Actin (mouse, ab8226, 1:2000; Abcam, 
mAbcam8226), DIS3 (rabbit, ab179933, GR:195524-7, 1:500, Abcam), Myc (mouse, 
clone 4A6, 1:1000; Millipore, 4A6), NAF1 (rabbit, ab157106, 1:1000, Abcam), RBM7 
(rabbit, HPA013993, 1:250, Sigma), SKIV2L2 (rabbit, ab187884, 1:500, Abcam), Tubulin 
(rabbit, ab6046, 1:5000; Abcam), ZCCHC8 (mouse, ab68739, 1:500, Abcam). Membranes 
were stained with anti-mouse or anti-rabbit IRDye secondary antibodies (IR680 or IR800, 
donkey, 1:10,000 for both) before visualization on an Odyssey scanner (LI-COR).  
Quantification of protein levels was done using ImageJ (80). 
 
Northern quantification of TR.  We optimized a protocol for quantifying TR levels using 
a modified northern protocol to maximize visualization of TR, a low abundance RNA.  
Total RNA (0.75-6µg) was mixed with RNA loading buffer (Sigma R4268-1VI) and 
heated to 95°C for 3m then cooled on ice for 3m.  Samples were then immediately loaded 
onto a pre-run Novex 6% TBE-UREA gel and run at 180V in heated TBE buffer (65°C) 
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for 55m on an Isotemp hot plate set to 70°C (Thermo Fisher Scientific).  Gels were 
transferred at 20V onto an Amerhsam Hybond-XL membrane for 90m (GE Healthcare Life 
Sciences). The cross-linking, hybridization and probe preparation were performed as 
previously described for hTR and 5.8S (18).  
 
Cloning and site directed mutagenesis.  Human ZCCHC8 (NM_017612), RBM7 
(NM_001286045), SKIV2L2 (NM_015360), and DIS3 (NM NM_014953.4) were cloned 
from total cDNA with addition of an N-terminal Myc-DDK tag into a CMV promoter 
driven pcDNA5/FRT/TO expression vector using restriction digestion and Gibson cloning 
(New England Biolabs). Plasmids were transfected using Lipofectamine 2000 or 3000 
(Invitrogen) and protein lysates were harvested after 24-48h. 
 
Transduction, lentivirus production and shRNA knockdown.  Virus production in HEK-
293FT cells, as well as the stable lentiviral shRNA knockdown in HeLa cells, were 
performed as previously described (18).   shRNAs were in PLKO.1 cloning vectors: 
Luciferase (SHC007, Sigma), NAF1 (TRCN000135721, Open Biosystems) and ZCCHC8 
(TRCN0000075158, Open Biosystems).   
 
Generation of ZCCHC8 null human cells. We used CRISPR/Cas9 editing to generate 
ZCCHC8 knockout HCT116 cells.  To first generate a ZCCHC8 knockout line, the sgRNA 
(5’ cccatccttcggaaagctga 3’, 20 bp) was cloned into the pX458 vector (gift from Feng 
Zhang, Addgene #62988) (81) and transfected into pseudodiploid HCT116 cells.  GFP-
positive cells were flow-sorted in bulk and re-plated using single-cell dilutions. Mutants 
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were screened for by PCR and Sanger sequencing (F: 5’ acacatcaaagtctggctcctt 3’, r: 5’ 
cggaaagctgagggttttc 3’).  
 
Cell line authentication. HCT116 cells (gift from Dr. Ben Ho Park, Johns Hopkins 
University) were authenticated by short tandem repeat profiling according ATCC 
guidelines using the PowerPlex 16HS short tandem repeat profiling kit (Promega) and 
matched ATCC# CCL-247 HCT116 human colon carcinoma lines according to the 
ANSI/ATCC ASN-0002-2011 standard (ANSI eStandard) (Johns Hopkins Genetic 
Resources CORE Facility). 
 
3’Rapid Amplification of cDNA Ends sequencing (3’RACE-seq). 3’RACE for TR was 
performed as previously described (17, 29) with modifications. Briefly, DNase I-treated 
(Qiagen) total RNA was ligated to 5µM pre-adenylated linker (Universal miRNA Cloning 
Linker, New England Bio Labs)with 280U T4 RNA ligase 2, truncated KO (New England 
BioLabs) in a 20μl reaction at 25°C for 16h with RNaseOUT and 25% PEG8000 (New 
England BioLabs).  The ligation reaction was then cleaned using RNA Clean and 
Concentrator (Zymo Research) and cDNA was synthesized with a universal RT primer (5’-
CTACGTAACGATTGATGGTGCCTACAG) using the SuperScript III Reverse 
Transcriptase (Thermo Fisher Scientific).  TR PCR was carried out using hTR_RACE_F 
and hTR_RACELinker_R (final 0.4 µM) (primer sequences available upon request), 
dNTPs (final 200 µM) and Q5 high fidelity DNA Polymerase (at 0.02 U/µl) (New England 
Biolabs) with these parameters: 98°C for 1m, 22 cycles of 98°C for 10s, 67°C for 30s, and 
a final extension at 72°C for 2 min. The product was then purified (QIAquick, Qiagen) and 
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visualized on agarose gels for quality control prior to library preparation. Libraries were 
prepared using the TruSeq Nano DNA LT Library Prep kit (Illumina) following the 
manufacturer’s instructions but starting with adenylation of 3’ends. Samples were 
quantified by Bioanalyzer diluted to 2nM each then pooled.  The combined libraries, 
containing 15-20% phiX control (Illumina), were then run on an Illumina MiSeq with 250 
paired-end reads (Johns Hopkins Genetic Resources Core Facilities).  
 
3’RACE-seq analysis. Reads were demultiplexed and the read 1 and read 2 fastq files for 
each sample were generated.  Reads were trimmed using a custom script. To quantify the 
length and sequence of short extensions (defined as up to 15 bases beyond the 451st 
nucleotide of the mature hTR end with or without an oligoA tail), reads were mapped to 
the reference genomic TR locus (NR_001566) appended with the linker sequence using 
Bowtie2(82) and extensions were determined as insertion blocks in the alignments. The 
mean number of reads mapped per sample was 200,745 (range, 79,000-301,000) and the 
median alignment rate was 80% (range, 42-89).  Because of the limited amount of RNA, 
the 3’RACE-seq from the ZCCHC8 RNA IP had a lower alignment (17%), corresponding 
to 132,550 reads.  Using a customized script, reads were then filtered to contain both at 
least 11 bases of the 3’ end of mature TR and at least 9 of the 17 bases of the linker 
sequence. The relative abundance of different 3’ termini for TR was determined by 
normalizing to the percentage of total trimmed and filtered reads.  
 
Long genomic extensions (i.e. >15 bases beyond the mature TR end) were quantified 
separately using Bowtie and Sim4db (83) to ensure mapping to the entire TR locus 
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including +/- 5 kb sequences flanking the mature TR. SAMtools were subsequently used 
to extract reads corresponding to the extended region >15 bases beyond the end of mature 
TR.  The mean number of reads mapped was 181,460 (range, 70,000-282,000) and the 
median alignment rate was 71% (range, 31-85).  Percent alignment for RNA 
immunoprecipitate (IP) was 16% with 124,020 reads aligning to the target TR sequence. 
Customized scripts for TR 3’RACE-seq analysis are available upon request.   
 
Telomerase Repeat Amplification Protocol (TRAP). TRAP was performed as previously 
described (84). HCT116 cells were treated with CHAPS lysis buffer (104 cells/µL) and 
isolated protein was quantified using a BCA assay as above.  
 
Protein and RNA IP. 293FT cells were grown to 75-90% confluence and transiently 
transfected with pcDNA5/FRT/TO/ZCCHC8-Myc-DDK plasmid using lipofectamine 
2000 reagent (ThermoFisher). After 48h, cells were washed with PBS supplemented with 
protease inhibitors (Roche) and lysed cells in buffer [20 mM Tris-HCl pH 7.5, 150 mM 
NaCl, 0.1% NP40, 2mM MgCl2, 1x EDTA-free Halt Protease, phosphatase inhibitor 
cocktail (ThermoFisher) and RNAsin (Promega)]. The lysate was rotated end-to-end at 4°C 
for 15m and clarified by spinning at 4°C for 10m at 12.3 rpm. The supernatant lysate was 
incubated with anti-c-Myc magnetic beads (Pierce) for 2h at room temperature, rotating 
end-to-end.  After washes in 1x TBS-T (25mM Tris, 0.15M NaCl, 0.05% Tween-20) and 
lysis buffer, one third of the sample was processed for protein IP and the rest for RNA IP. 
For protein IP, the bound protein was eluted with NuPAGE LDS Sample Buffer (4X) and 
then diluted to 2X with Lysis Buffer.  For RNA IP, the beads were resuspended in TriZol, 
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incubated at -80°C overnight and RNA was extracted as a co-precipitate based on the 
manufacturer’s protocol (Life Technologies).  The isolated RNA was treated with DNAse 
(Ambion, AM1906) and used as a template for cDNA synthesis using Superscript III 
reverse transcriptase (Invitrogen) and random hexamer primer mix (Thermo Fisher 
Scientific). TR was then amplified by RT-PCR using the same primer set used for total TR 
quantification described elsewhere here. Alternatively total RNA was used for TR 
3’RACE-seq. 
 
Statistical analyses. Singlepoint parametric linkage was analyzed using logarithm of the 
odds scores.  qRT-PCR analyses were reported as standard error of the mean (s.e.m.), and 
P values were calculated using GraphPad Prism software.  For each PCR run, samples were 
done in triplicate.  All P-values shown are two-sided. Statistical tests uses are indicated in 






Loss of ZCCHC8 in mice leads to severe 
neurodevelopmental defects 
Dustin L. Gable1,2,3, Valeriya Gaysinskaya2,3, Christine C. Atik2,3, C. 
Conover Talbot Jr.4, Byunghak Kang5, Nuria Amat-Codina2,3, Cory 




Medical Scientist Training Program1 
Department of Oncology2 
Telomere Center3 
Institute for Basic Biomedical Sciences4 
Department of Comparative and Molecular Pathobiology5 
McKusick-Nathans Institute of Genetic Medicine6 
Sidney Kimmel Comprehensive Cancer Center7 
Johns Hopkins University School of Medicine 





We have shown that ZCCHC8 knockdown in HeLa cancer cell lines is sufficient to 
decrease TR levels and HCT116 cancer cells null for ZCCHC8 are viable but deficient for 
telomerase activity; however, additional RNA processing defects secondary to complete 
ZCCHC8 loss remain unknown. Previous work in HeLa cells elucidating additional 
ZCCHC8 functions are limited but support a role for ZCCHC8 in non-nucleolar 
localization and processing of PROMoter uPstream Transcripts (PROMPTs). Other RNA 
targets of ZCCHC8 and consequences of its loss in connection with the NEXT complex 
have remained elusive requiring further study (37). Our studies in NAF1 mutant mice 
highlight the dosage sensitivity of telomerase RNA (TR) stability such that heterozygous 
loss selectively disrupts telomerase RNA levels with sparing of RNA pseudouridylation 
while homozygous loss is embryonic lethal pointing to the essential NAF1 functions 
beyond telomerase RNA maintenance likely in rRNA modifications given TR null mice 
are viable (18).  Similarly we would hypothesize that additional regulators of telomerase 
RNA biogenesis including ZCCHC8 would exhibit TR dosage sensitivities such that 
heterozygous loss perturbs telomerase RNA homeostasis sufficient to cause telomere 
shortening whereas homozygous loss has additional biological consequences beyond 
defective processing of nascent TR.  
 
In order to perform hypothesis driven experiments and identify consequential RNA 
processing defects secondary to ZCCHC8 loss in a biologically and clinically relevant 
model we engineered ZCCHC8 null mice in a C57BL/6J background. Observed 
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phenotypes would then be secondary to non-telomeric function of ZCCHC8 given the 
long telomeres (40 kb) in this strain of mice that would require substantial number of 
backcrosses for any relevant measurable phenotype effect seen in mice with telomere 
lengths similar to human (55, 85). In both mice and humans, TR is haploinsufficient for 
telomere maintenance.  TR+/- mice with telomere lengths similar to humans show 
genetic anticipation, and late generation mice with short telomeres develop bone marrow 
failure and other short telomere syndrome phenotypes (6, 15, 55). While Zcchc8+/- mice 
had TR insufficiency but were otherwise intact, as expected for first generation 
telomerase null mice, Zcchc8-/- mice showed severe neurodevelopmental defects that 
overlapped with features of a ciliopathy.  In these Zcchc8-/- mice, there was a pervasive 
RNA dysregulation defect that included accumulation as well as mis-processing of RNAs 
encoding cilia components as well as replication dependent histones (RDH).  These 
transcripts shared a similar length to TR.  Our data indicate that vertebrate TR requires 
ZCCHC8 for its maturation, along with other low abundance RNAs.  In contrast to 
complete ZCCHC8 loss, however, which manifests as a pervasive transcriptome defect, 
heterozygous mutations preferentially affects TR and manifests in TR insufficiency and a 
familial short telomere syndrome.  
RESULTS 
Zcchc8 loss causes a gene dose-dependent misprocessing and overall insufficiency of 
TR  
To test the consequences of ZCCHC8 loss in vivo, we used CRISPR/Cas9 to edit the mouse 
Zcchc8 locus (Figure 13A).  We were particularly interested in this question since we noted 
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mention in the literature of one family with homozygous null mutation in ZCCHC8, L90X, 
that was identified in a study examining genetic determinants of autosomal recessive 
intellectual disability in consanguineous families (86).  The genome editing strategy we 
designed introduced a null allele with a premature stop codon at amino acid 93 in exon 2 
of mouse Zcchc8 (Figure 13A).  We interbred heterozygous mutant mice and detected 
viable heterozygous and homozygous null progeny that had half and no detectable 
ZCCHC8, respectively (Figure 13B).  These data suggested that Zcchc8 is not essential for 
embryogenesis (Figure 13B).  In cells derived from adult Zcchc8+/-, we found the levels of 
other NEXT complex proteins, RBM7 and SKIV2L, were preserved similar to the human 
patient (Figure 13B), while Zcchc8-/- knockout mice had minimally decreased levels of 
these proteins (Figure 13C and antibody cross-reactivity validated and data not shown).  
These data suggested that the stability of RBM7 and SKIV2L2 does not depend on 
ZCCHC8 integrity.  To assess the consequences of ZCCHC8 loss on TR, we measured total 
TR levels by northern blot and found that, similar to mTR+/- mice, total TR was decreased 
in both Zcchc8+/- and Zcchc8-/- mice (P=0.02 for both, Student’s t-test, Figure 13D-E).  
Because TR in these Zcchc8 mutant mice may include aberrant non-functional forms, total 
levels by this northern analysis may under-estimate the extent of the TR insufficiency in 
these mice.  We specifically quantified mTR precursors by amplifying 3’extended products 
that were at least 20 nt long by qRT-PCR and found that Zcchc8+/- and Zcchc8-/- had a dose-
dependent increase with Zcchc8-/- mice having the highest levels (Figure 13F).  These data 
affirmed that ZCCHC8 plays a role in vertebrate TR 3’end processing and that this effect 
is dose-dependent.  
Zcchc8-/- mice develop a progressive fatal pathology 
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We next examined the vivo consequences of Zcchc8 loss. The interbreeding of Zcchc8+/- 
mice revealed a distortion of Mendelian ratios in their progeny with Zcchc8-/- representing 
only 5% of adult mice surviving to day 30 (P<0.001, chi-square test, n=170 mice 
genotyped, Figure 13G).  The viable mice developed a progressive decline and none  
survived beyond 70 days.  Their attrition occurred postnatally as Zcchc8-/- Mendelian ratios 
were preserved for both E12.5 embryos as well as newborn pups (Figure 13G).    
 
Zcchc8+/- mice are intact but Zcchc8-/- littermates exhibit a progressive 
neurodevelopmental defect  
To characterize the consequences of ZCCHC8 loss in vivo, we first studied adult Zcchc8+/- 
mice and found they were grossly and histologically indistinguishable from wild-type 
littermates (Figure 14A).  Specifically, we found no abnormalities in the organs examined 
including the brain, viscera and hematopoietic system (n=9/genotype examined, 5 males/4 
females).   These observations were consistent with Zcchc8+/- mice primarily having TR 
insufficiency that is predicted to cause telomere shortening after many successive 




Figure 13. Design of Zcchc8 targeting strategy using CRISPR/Cas9.  A. Scheme depicts CRISPR 
targeting of exon 2 within the sgRNA binding site that is 3 base pairs upstream of the PAM sequence to 
incorporate a 33 base pair insert (arrows) containing a stop codon (red). BamH1 restriction site and the FLAG 
sequence identify edited alleles. The screening strategy uses a forward primer in the edited exon and a 
downstream intronic reverse primer (black arrows).  B and C. Immunoblot for ZCCHC8 and SKIV2L2 and 
RBM7 protein in mouse skin fibroblasts. D and E. Northern blot for mouse TR (mTR) levels quantified 
relative to 5.8S rRNA in skin fibroblasts. For (E), mean reflects mice Zcchc8+/+ (n=4, 2M/2F), Zcchc8+/- 
(n=4, 2M/2F), Zcchc8-/- (n=3M), mTR+/- (n=2, sex unknown) and mTR-/- (n=2, sex unknown). F. mTR 3’-
extended levels (>20 bp) relative to Hprt as measured by qRT-PCR.  Mouse numbers and sex designations 
are as in E. Data in B-F are from mouse adult ear fibroblasts.  G. Genotype frequency from Zcchc8+/- 
interbreeding of E12.5 embryos, newborn pups (P0), and day 30 adult mice with the number of each genotype 
screened shown.  Data are expressed as means ±SEM. *P < 0.05, **P < 0.01, and ***P < 0.0001 (Student’s 
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In contrast, adult Zcchc8-/- mice had evident cranial abnormalities with domed-shaped 
heads, a sign of hydrocephalus (Figure 14A, top panel).  Computed tomography (CT) 
imaging confirmed cranial deformities with dilated cranial sutures (Figure 14A, middle and 
lower panels, respectively). We performed a detailed histologic analysis and found that 
nearly all Zcchc8-/- mice that survived at least 30 days had severe hydrocephalus with 
ventriculomegaly (9 of 11, Figure 14B). In mice, hydrocephalus is a common manifestation 
of ciliopathy; it arises because of defects in ependymal motile cilia that in turn impair 
cerebrospinal fluid movement (88).  We therefore examined Zcchc8-/- mice for other 
ciliopathy features and found a high prevalence of severe otitis media, another phenotype 
caused by defects in motile cilia lining the middle ear mucosa (8 of 10).  We, however, did 
not find evidence for laterality defects, such as situs  
 
inversus or heterotaxy (data not shown). Moreover, there was no evidence of upper airway 
disease as is seen with some motile ciliopathies.  To assess the cause of the cranial defects, 
we traced brain development in Zcchc8-/- embryos and found they had grossly small crania 
and brain volumes, indicating a defect in neurogenesis preceding the onset of 
hydrocephalus post-natally (Figure 14C-D).  Zcchc8-/- embryos and newborn pups were 
also microcephalic, but developed macrocephaly by the time they reached adulthood 
(Figure 14F-G).  These data indicated that Zcchc8-/- mice develop a progressive 







Figure 14. ZCCHC8 loss causes a neurogenesis and hydrocephalus defect in adult knockout mice, but 
heterozygous mice are intact. A. (Top row) Images showing head profile of Zcchc8 wild-type, heterozygous 
and homozygous null mice (41-46 days old). The labels show the genotype with a male (left) and a female 
(right) shown for each genotype.  Zcchc8-/- mice have abnormal head profile with dome cranium and pointed 
nose as outlined by the dashed line.  (Middle row) CT head mid-sagittal images show intact skull shape in 
Zcchc8+/- mice, while Zcchc8-/- mice dome-shaped crania. (Bottom row) Volume-rendered (VR) CT images 
of mouse calvaria show widened cranial sutures in Zcchc8-/- mice (3 of 6 imaged). None of the Zcchc8+/+ (0 
of 4) or Zcchc8+/- mice (0 of 4) imaged had this feature.  Each vertical group of images is from the same 
mouse except the last column (2 different females).  B. Representative H&E coronal sections from 8-week 
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old male heads show no defects in Zcchc8+/- (11 examined) compared to Zcchc8+/+ mice (10 examined). In 
contrast, Zcchc8-/- mice have severe ventricular dilation (seen in 9 of 11 examined).  C. E12.5 brain sections 
show Zcchc8-/- have microcephaly but intact brain structures and no ventriculomegaly. D. E12.5 embryos 
from a single dam show expected Mendelian ratios but Zcchc8-/- embryos have small crania.  E. Cranial area 
of P0 pups measured on VR CT images using ImageJ (Zcch8+/+ n=7, 3M/4F; Zcch8+/- n=10, 3M/7F; Zcch8-
/- n=4, 3M/1F). F. Cranial area as in E with best fit curve (second order polynomial quadratic) showing 
Zcchc8-/- mice become macrocephalic between birth and adulthood reflecting their hydrocephalus (Zcchc8+/+, 
n=4, 3M/1F; Zcchc8+/-, n=4, 3M/1F; Zcchc8+/-, n=5, 3M/2F).  Dashed lines denote the 95% confidence 
intervals.  F. Total body weight of adult male mice (42 to 63 days old, Zcch8+/+, n=20; Zcch8+/-, n=13, Zcch8-
/-, n=5). E and F show mean values ±SEM. **P<0.01 (Student’s t-test, two-sided). 
Global RNA analysis shows Zcchc8-/- developing brains have defective turnover of 
RNA polymerase II low abundance transcripts 
The mouse phenotypes we documented indicated that, while Zcchc8 heterozygous loss is 
well- tolerated, as would be expected for first generation mice that have telomerase 
insufficiency, complete Zcchc8 loss caused severe neurodevelopmental defects. To better 
understand the basis for this in Zcchc8-/- adult mice, we performed RNAseq on E12.5 
brains.  We chose this timepoint in development because the Mendelian ratios were 
preserved (Figure 13G).  We prepared the libraries using an adenylated RNA selection to 
focus the analysis on protein-coding genes.  In a hierarchical analysis, and using no 
supervision, each of the three Zcchc8 genotypes clustered separately, but there was an 
obvious deviation in the Zcchc8-/- gene expression pattern from wild-type and heterozygous 
brains (Figure 15A).  In a volcano plot analysis, we found little difference when we 
compared Zcchc8+/- and Zcchc8+/+ transcriptomes (Figure 15B). However, the 
transcriptome from Zcchc8-/- embryos showed a skewed and upregulated pattern relative 
to wild-types (Figure 15C). Among these upregulated genes, adenylated TR had a linear 
6.8-fold higher level relative in Zcchc8-/- compared to wild-type levels (+5.9 standard 
deviations in the ordered gene comparisons, P=1.72x10-8, with a one-way two-tailed 
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ANOVA) despite total TR being down (Figure 13D.   We analyzed 3’ends of the TR 
queried in the RNA-seq library and found Zcchc8-/- embryos had more extended TR forms 
than wild-types and heterozygotes (P=0.02 relative to the latter comparison) with Zcchc8+/- 
embryos showing an intermediate phenotype (Figure 15D).  Notably, the increase in 
3’elongated nascent transcripts was specific to the upregulated genes and was not seen for 
other RNA pol II genes which had no change in overall levels (e.g. Arf1 and Arf3) nor for 
RNA pol III non-coding RNAs such as Rmrp (Figure 15D).  These data suggested that the 
increased adenylated TR levels are in Zcchc8-/- are the aberrant forms similar to what we 
saw in human mutant cells. 
 
We next examined the identity of these most highly upregulated genes in the Zcchc8-/- vs. 
Zcchc8+/+ analysis (defined as group with >2SD-fold change). TR is a low abundance 
RNA, and we found that the most upregulated genes fell within the lowest FPKM values 
in the wild-type distribution (P<1x10-8, Mann-Whitney test and Bootstrap analysis, Figure 
15E).  This pattern was in contrast to the more broad distribution of the most 
downregulated gene (defined as >2 SD-fold change) in the same Zcchc8-/- vs. Zcchc8+/+ 
comparison (Figure 15E). These data suggested that ZCCHC8 is involved in the processing 




Figure 15. Zcchc8-/- mice show an upregulation of low abundance adenylated RNAs including TR. A. 
Heatmap and dendrogram of gene expression showing unsupervised analysis of 9,788 genes.  Colors denote 
mean-subtracted FPKM expression values on a log2 scale. Zcchc8+/+ n=5, Zcchc8+/- n=3, Zcchc8-/-, n=6 
embryonic brains.  Each column is labeled below by WT, HET, KO followed by the embryo number 
1,2,3…etc. and refer to respective Zcchc8 genotypes.  The log2 expression value was subtracted from the 
mean log2 expression value of the entire cohort. The dendrogram showing relatedness of the samples is above, 
and relatedness of the gene transcripts is to the left. The differential change in gene expression is shown as 
positive and negative change on color scale indicated in key.  B and C. Volcano plots depicting the log2-fold 
changes (x-axis) vs. –log10 P-values calculated by two-tailed one-way ANOVA of RNA-seq expression data 
(y-axis) for the Zcchc8+/- and Zcchc8-/- vs. Zcchc8+/+ comparisons, respectively.  Each dot represents a single 
transcript. D. Extended reads defined as ≥15 bases beyond the mature RNA end for each of TR and Rmrp is 
shown. Data were normalized to total Arf3 reads per embryo and each dot represents values from an embryo. 
Error bars represent s.e.m and P-value is calculated based on a two-sided Student’s t-test. E. Histogram of 
number of genes at each expression value denoted on the x-axis by the mean log2FPKM values obtained from 
Zcchc8 wild-type embryos (n=5). Genes that have > 2 SD higher levels in the Zcchc8+/+ vs. Zcchc8-/- 
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mean FPKM in wild-type embryos shown.  The downregulated genes defined as <2 SD (n=42) are shown in 
blue and appear uniformly distributed on the distribution. 
 
Zcchc8 is required for post-transcriptional processing of a subset of replication-
dependent histones and some motile cilia components in addition to TR 
We examined other transcript characteristics of the upregulated, low abundance genes and 
found that a large subset, 22% (42 of the 188 with known gene structure), were, like TR, 
intronless and transcribed by RNA polymerase II (Figure 16A).  Notably, most of these 
intronless transcripts had similar length to TR, between 400 and 500 nucleotides (Figure 
16B).  When we examined the identity of the intronless genes, we found a striking 
enrichment of two subsets. The first were histone genes which comprised more than half 
(23 of 42, 55%).  Almost all of these, 22 of 23, were Replication-Dependent Histones 
(RDH) (Figure 16B).  The mouse genome has 65 RDH genes and most of these, 51 of 65 
(78%), fall in the major histone cluster on mouse chromosome 13(89).  Our analysis 
enriched for nearly half of these (22 of 51 RDH vs. 55 RDH of 9,788 total high quality 
transcripts, P<0.0001, Fisher’s exact test).  The second subset involved intronless genes 
with coiled-coil domains that encode cilia components (Figure 16A-B). Motile cilia on 













Figure 16. Telomerase RNA shares a requirement with replication-dependent histones (RDH) and 
some cilia genes for Zcch8-dependent 3’-end processing. A. Histogram of the most upregulated (>2SD) 
transcripts in the Zcchc8-/- vs. Zcchc8+/+ by exon number shows the largest category are intronless (42 of 188 
with known gene structure, 22%). The pie charts divides the intronless genes by functional category.  B. 
Annotation of 28 upregulated intronless genes (TR, histones and cilia) shows a majority of the histones 
represented are RDH (23 of 24, 96%). The vast majority also have an annotated transcript size in the range 
of TR (NCBI Gene database, https://www.ncbi.nlm.nih.gov/gene, accessed 1/1/2019) between 400 and 560 
(22 of 28).  The 3’ and 5’end analyses denote longer ends at each of these mature RNA boundaries in Zcchc8-
/- as manually visualized in Integrative Genomic Viewer (IGV).  Columns refer to 5’end and 3’end refer to 
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Gene                          Function Transcript Length (nt) 5’-end 3’-end
TR T elom eras e 3 97 - + 
Hist1h1b R D H  794 + + 
H2afy2 In depen den t 4 5 2 18 - + 
Hist1h2ab R D H  5 05  + + 
Hist1h2ae R D H  5 5 8 - + 
Hist1h2ai R D H  448 - + 
Hist1h2ak R D H  5 3 6  - + 
Hist1h2an R D H  447 - + 
Hist1h2bf R D H  4 3 1 - + 
Hist1h2bg R D H  4 6 4 - + 
Hist1h2bj R D H  4 2 9 + + 
Hist1h2bk R D H  5 00 - + 
Hist1h2bm R D H  483  + + 
Hist1h2bp R D H  4 5 6  - + 
Hist1h3c R D H  480 + + 
Hist1h3e R D H  470 + - 
Hist1h3h R D H  488 - + 
Hist1h3i R D H  483  + + 
Hist1h4b R D H  4 5 0 + + 
Hist1h4c R D H  3 75  + + 
Hist1h4d R D H  3 6 8 + + 
Hist1h4j R D H  4 2 3  + - 
Hist1h4m R D H  405  - + 
Hist2h2be R D H  2 6 6 7 + - 
Hist3h2ba R D H  4 6 2  - - 
Ccdc89 M otile cilia 2 3 5 3  + - 
Ccdc96 M otile cilia 3 5 84 - - 
Ccdc182 M otile cilia 12 19 + + 
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presence of additional reads beyond these boundaries with 5’end reads usually referring to upstream reads 
that are not necessarily contiguous.  C and D. Genome browser sashimi plots from IGV viewer showing 
extended 3’ends as labeled above from two representative histone genes Hist1h1b and His1h2bp in each of 
Zcchc8+/+, Zcchc8+/-, Zcchc8-/- transcriptomes, respectively. E and F. Sashimi plots for two coiled-coil 
domain containing cilia genes Ccdc89 and Ccdc182, respectively by genotype. For Ccdc89, in addition to 
accumulation of reads beyond the mature 3’-end in the Zcchc8-/- transcriptome, there is also an increase in 
discontinuous upstream of gene 5’end reads that resemble so-called PROMoter uPstream Transcripts 
(PROMPTs). 
 
cerebrospinal fluid circulation, and their dysfunction could explain the hydrocephalus-
otitis phenotype we saw in Zcchc8-/- mice.  In total, among the most aberrantly processed 
upregulated polyadenylated genes, there were five coiled-coil domain genes involved in 
ciliagenesis. In addition, there were transcripts that encode transmembrane proteins 
(Tmems) that are involved in formation of the ciliary transition zones (n=4).  ZCCHC8 
was also required for the turnover of Dnah7b, an essential component of the dynein 
axonemal heavy chain of cilia (90), as well as the intraflagellar transporter Ttc26 for which 
mutations are known to cause hydrocephalus in mice (91). 
 
Replication-dependent histones and cilia transcripts show end processing defects like 
TR 
We next asked whether the upregulation of RNAs in the Zcchc8-/- transcriptome, similar to 
TR, reflects a misprocessing defect. We manually examined the intronless RDH and cilia 
genes along with TR and found that, in addition to their overall increased abundance, most 
of them (22 of 28) had a 3’end defect marked by genomically-encoded extensions of 
variable length beyond the annotated 3’end (Figure 16B and examples in Figures 16C-
F).  This was true for both the RDH and cilia genes we examined (Figures 16B-F).  We 
additionally noted that at least half of these genes (14 of 28) also had accumulated upstream 
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reads that were discontiguous with the 5’gene end and resembled so-called PROMoter 
uPstream Transcripts (PROMPTS) that have been reported with depletion of NEXT and 
nuclear RNA exosome components (92).  
DISCUSSION  
This segmental phenotype associated with TR insufficiency is evident in the intact 
phenotype of first generation Zcchc8+/- mice relative to Zcchc8-/- mice. The transcriptome 
was an enrichment of dysregulated polyadenylated RNAs and misprocessed genes 
involved in ciliogenesis and these are potential candidate genes for a secondary ciliopathy 
in Zcchc8-/- mice and suggest a possibility that some RNA dysregulation syndromes, such 
as those caused by ZCCHC8 mutations in humans, may overlap in their features with 
ciliopathies.  Our observations are notable since the mouse model we generated may be the 
first to study the mammalian consequences of mutations in an RNA exosome targeting or 
an RNA exosome-related gene. 
 
 Several RNA dysregulation syndromes have been described and they share defects in 
neurodevelopment.  For example, biallelic mutations in EXOSC3 have been linked to 
pontocerebellar hypoplasia, and mutations in EXOSC8 cause vision and hearing loss, but 
both of these genes are components of the cytoplasmic as well as nuclear RNA exosomes 
[reviewed in (93)].  Homozygous mutations in RBM7 have been described in one patient 
with spinomuscular atrophy who was cognitively intact at 2 years of age (94).  These 
phenotypes contrast with the phenotype of autosomal recessive intellectual disability that 
was found in one of 136 families associated with homozygous null mutations in ZCCHC8 
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(86).  These observations in light of our data may suggest that neurodevelopment is 
particularly susceptible to inherited defects in RNA processing genes. 
 
The analysis of RNAs in Zcchc8-/- embryos shows that in the homozygous null state, there 
was dysregulation of low abundance, RNA polymerase II transcripts. Many of these RNAs 
shared a similar length with TR.  Low abundance genes were recently identified to be 
enriched in mouse embryonic stem cells that were depleted for the non-catalytic nuclear 
RNA exosome component RRP40 (95).  Our studies in ZCCHC8 deficient animals, in light 
of these published data suggest that, through yet-to-be characterized mechanisms, 
ZCCHC8 and the nuclear RNA exosome preferentially are involved in the processing of 
low abundance polyadenylated RNAs including TR.  The RNA species that are 
preferentially targeted to the RNA exosome by ZCCHC8 have not been previously studied.  
Prior studies using HeLa cell lines and iCLIP data from over-expression of tagged RBM7, 
another component of NEXT, found an association with replication dependent histones 
(RDHs) but suggested a role for the RNA exosome in nascent RDH turnover (92, 96). Our 
data from the developing mouse transcriptome support that but suggest that ZCCHC8 is 
also required for RDH 3’end processing, in addition to turnover, for at least a subset.  
Classically, RDH mRNAs are thought to be not polyadenylated but have a unique 3’end 
stem-loop structure that is required for their endonucleolytic cleavage (97). Recent data, 
however, from transcriptomes of terminally differentiated tissues found that a subset of 
RDHs are indeed polyadenylated (98), similar to our data.  Specifically, we find that there 
are at least some settings where RDH mRNA is adenylated and requires nuclear RNA 
exosome targeting for its turnover as well as 3’end processing.  
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 Overall, we show that vertebrate TR shares a requirement for ZCCHC8 targeting to the 
nuclear RNA exosome together with at least a subset of RDH genes and other low 
abundance polyadenylated RNAs.  When genetically disturbed, this misprocessing leads 
to TR insufficiency and telomere-mediated disease in heterozygous loss and a more severe 




Quantitative Real Time-PCR (qRT-PCR) for TR. RNA levels were measured using the 
SYBR Green qRT-PCR method as previously described (18). Briefly, RNA was isolated 
(RNeasy, Qiagen) and reverse transcribed using random hexamer primers and Superscript 
III (Invitrogen). Within any given experiment, RNA isolation and cDNA reverse 
transcription were side-by-side for all the samples.  TR levels were normalized to ARF3 
(human) and Hprt (mouse).  Primer sequences for mTR qRT-PCR both total and extended 
forms available upon request.   
 
Western blots. Total protein was isolated from cells in RIPA buffer (Cell Signaling 
Technology) with cOmplete Mini protease inhibitor (Sigma-Aldrich) and lysates were 
quantified using Pierce BCA Protein Assay Kit (Thermo Fisher Scientific). Using the 
NuPAGE SDS-PAGE gel system, protein (10-20µg) was run on 10% Bis-Tris gels with 
MOPS-SDS running buffer at 150V and transferred to a PVDF membrane by wet transfer 
using XCell SureLock Mini-Cell Elecrophoresis System or by the iBlot 2 Dry Blotting 
System at 30V (Thermo Fisher Scientific). Immunoblotting was performed using the LI-
COR system as previously (18). Membranes were blocked for 1h to overnight prior to 
antibody staining. The following antibodies were used with clone identifiers listed for the 
two monoclonal antibodies (Actin and Myc): Actin (mouse, ab8226, 1:2000; Abcam, 
mAbcam8226), Myc (mouse, clone 4A6, 1:1000; Millipore, 4A6), RBM7 (rabbit, 
HPA013993, 1:250, Sigma), SKIV2L2 (rabbit, ab187884, 1:500, Abcam), Tubulin (rabbit, 
ab6046, 1:5000; Abcam), ZCCHC8 (mouse, ab68739, 1:500, Abcam). Membranes were 
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stained with anti-mouse or anti-rabbit IRDye secondary antibodies (IR680 or IR800, 
donkey, 1:10,000 for both) before visualization on an Odyssey scanner (LI-COR).  
Quantification of protein levels was done using ImageJ (80). 
 
Northern quantification of TR.  We optimized a protocol for quantifying TR levels using 
a modified northern protocol to maximize visualization of TR, a low abundance RNA.  
Total RNA (0.75-6µg) was mixed with RNA loading buffer (Sigma R4268-1VI) and 
heated to 95°C for 3m then cooled on ice for 3m.  Samples were then immediately loaded 
onto a pre-run Novex 6% TBE-UREA gel and run at 180V in heated TBE buffer (65°C) 
for 55m on an Isotemp hot plate set to 70°C (Thermo Fisher Scientific).  Gels were 
transferred at 20V onto an Amerhsam Hybond-XL membrane for 90m (GE Healthcare Life 
Sciences). The cross-linking, hybridization and probe preparation were performed as 
previously described for mTR and 5.8S (18).  
 
Cloning and site directed mutagenesis.  Mouse RBM7 (NM_144948) and mouse Skiv2l2 
(NM_028151) were cloned from total cDNA with addition of an N-terminal Myc-DDK tag 
into a CMV promoter driven pcDNA5/FRT/TO expression vector using restriction 
digestion and Gibson cloning (New England Biolabs). Myc-tagged mouse ZCCHC8 cDNA 
(NM_028151) cDNA was purchased in a pCMV3 expression vector (MG51487-NM, Sino 
Biological). Plasmids were transfected using Lipofectamine 2000 or 3000 (Invitrogen) and 
protein lysates were harvested after 24-48h. 
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Mouse study approval, maintenance and genotyping. The mouse studies were reviewed 
and approved by the Institutional Animal Care and Use Committee and the procedures 
conformed with the Guide for the Care and Use of Laboratory Animals (99). Mice were 
housed in the Johns Hopkins University School of Medicine East Baltimore campus. All 
the mice were on  a pure C57BL/6J background.  mTR null mice were derived and 
maintained as previously described (87).  The derivation of Zcchc8 null mice is described 
below and these mice were genotyped primers which amplified 363 bp and 396 bp products 
for the wild-type and mutant allele, respectively.  Sperm from mice carrying the null Zcchc8 
allele was deposited in the Jackson Laboratories Biorepository, Maine (Stock ID 404814). 
 
Generation of Zcchc8 null mice. We designed a CRISPR/Cas9 strategy to disrupt the 
Zcchc8 allele by zygote injection of a sgRNA targeting exon 2 (5’ tgaacattctgacaagaccc 3’, 
20 bp), and a DNA oligo for homology directed repair (HDR) and Cas9 protein. The HDR 
oligo  (5’ aagaacttaaaagaaagttgaacattctgacaagaGGATCCGATT 
ACAAGGACGACGATGACAAGTAGcccaggtatgacatcttgaaattacacacgagctg 3’, 103 bp) 
targeted a 33 bp insertion using 35-base pairing flanking homology arms which introduced 
a premature stop codon at amino acid 93 (P83delinsGSDYKDDDDK*) as well as a BamHI 
site and FLAG-tag sequence (Figure 5A).  To facilitate a genetic screen for the edited 
alleles, we used DDK sequence specific primers that fell within the FLAG-tag sequence 
(Figure 5A).  Injections into C57BL/6J zygotes were performed at the Johns Hopkins 
Transgenic Mouse Core Facility. Founder mice were back-crossed to wildtype C57BL/6J 
two times prior to interbreeding of ZCCHC8+/- mice. 
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Mouse phenotyping and pathology.  Mouse ear fibroblasts were derived and maintained 
as described previously (18).  Mice were individually euthanized by exposure to gradually 
increasing concentrations of CO2 then exsanguination by cardiocentesis and perfusion with 
heparinized saline, then 10% NBF via left cardiac ventricle. Perfused tissues were fixed in 
10% NBF for at least 24h prior to trimming. The head and hindlimb were separately 
decalcified with Formical 4 (StatLab Medical Products, TX). Gross examination and tissue 
collection was performed as described in (Brayton 2014 Anaylsis of Phenotype).  Sections 
(~5µm) were stained with hematoxylin and eosin and reviewed by two veterinary 
pathologists (BK and CB).  Image capture was performed on a Nikon 55i microscope and 
slides were scanned at 20x on an Aperio AT2 instrument (Leica Biosystems, IL).   
 
Computed tomography (CT) imaging and image analysis.  Mice were anesthetized using 
isoflurane prior to and during imaging. Gross images of the mice’s heads were taken using 
a phone camera. CT imaging was performed using the nano PET/CT Small Animal Imager 
(Mediso) (Johns Hopkins Center for Infection and Inflammation Imaging Research). CT 
images were visualized on RadiAnt DICOM Viewer (v.4.6.5.18450, 64-bit, 
Medixant). Using the CT Bone setting, mid-sagittal CT images were acquired using the 3D 
Multiplanar Reconstruction viewer to align the axes to the middle of the nasal cavity and 
incisors in the coronal and axial settings respectively. Virtual reconstruction CT images 
were generated using the 3D Volume Rendering function and saved in the Bones and Skin 
3 setting. Cranial area was measured as a surrogate for brain volume using the polygon 
selection tool of ImageJ.  To ensure there are no sex-specific phenotypes, for newborn pup 
imaging studies, we assessed male/female by PCR as described in (100). 
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RNAseq isolation, library preparation and sequencing. E12.5 brains were isolated and 
the ftissue was placed into RNAlater (Qiagen) then homogenized in a Bullet Blender using 
zirconium oxide coated beads (Next Advance).  RNA was prepared using RNAeasy kit 
(Qiagen).  Libraries were prepared for RNAseq using the standard protocol for Truseq 
Stranded mRNA Library preparation (Illumina).  The sequencing was completed using 
NovaSeq S1 flowcell paired end 150 bp. This generated 253 million 150 bp long paired-
end reads per sample (range 195-321 million), of which 95.8% on average (range 90.9 to 
96.6%) mapped to the mouse genome following the procedure described below.   
 
RNAseq bioinformatics. Transcriptomic data collected by RNA-seq were analyzed to 
determine the genes that are present in each sample, their expression levels, and the 
differences between expression levels among different genotypes.   Alignment and 
annotation.  Following quality checking with the software FastQC (v. 0.10.0 )(101), reads 
were end-trimmed to 100 bp and mapped to the mouse genome version mm10 with the 
alignment tool Tophat2 v.2.1.0 (102). Between 91%-97% of reads per sample mapped to 
the mouse genome, of which a very small fraction (1.5%-1.9%) had multiple matches, and 
the concordant read fraction was 87.8%-94.4%.  The aligned reads were assembled with 
CLASS2 v.2.1.7 (103) to create partial gene and transcript models (transfrags). Transfrags 
from all samples were further merged with Cuffmerge (v. 2.2.1) (104) and mapped to the 
GENCODE v.M17 (https://www.genecodegenes.org) gene models, to create a unified set 
of gene annotations for differential analyses. Gene and transcript expression levels (in 
FPKM) were then computed with the tool Cuffdiff2 v.2.2.1 (105) and differentially 
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expressed genes (transcripts) were determined by statistical analysis.  The alignment and 
annotation were performed in August 2018. 
 
Gene expression analysis.  Differential gene expression analyses were performed using 
the FPKM files comprising 67,811 transcripts each generated as described above for each 
embryonic sample. The transcript identifiers were derived from these FPKM files’ “gene” 
column and updated to current nomenclature. The raw FPKM values of 0.0 were treated as 
nulls and actual values were transformed into log2 annotation and quantile normalized 
across the 14 samples. The three biological classes’, KO, HET, and WT, normalized signals 
underwent differential expression analysis with a two-tailed one-way t-test ANOVA using 
the Partek GS 6.16.0812 platform. A standard deviation analysis was performed for each 
class-class comparison using those transcripts that had high quality data: an NCBI Entrez 
gene ID, a mean FPKM linear value >2.0 in at least one cell class, and a non-zero FPKM 
signal value from all the 14 samples.  On the order of 9.5K transcripts met these three 
criteria for each cell-class comparison and were used for subsequent downstream 
functional analyses.  The raw data were deposited in the National Center for Biotechnology 
Information Gene Expression Omnibus database GEO (#GSE126108).  
 
RNAseq 3’-end analysis.  To elucidate the presence of 3’ extensions for mTR and mRmrp, 
and for relative abundance comparisons among Zcchc8+/+, Zcchc8+/-,  and Zcchc8-/-  mice 
(14 samples), we extracted RNA-seq read pairs partially aligning to the gene from the 
mouse RNA-seq Fastq files generated as part of the RNAseq bioinformatic analysis. Reads 
were then processed using the protocol described for 3’RACE-seq data with some 
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modifications, described herein. Briefly, reads (and fragments) mapping to the target gene 
were determined with Bowtie2 (82) with the option ‘-local’. Reads were then trimmed of 
Illumina adapters using the tool cutadapt (106), and an artificial ‘tag’ consisting of the 28 
bp linker sequence ACTGTAGGCACCATCAATCGTTACGTAG was added to the 3’ 
ends of forward mapping reads, whereas the reverse complement linker sequence was pre-
pended to the 5’ end of the reverse mapping reads. Similarly, the linker sequence was 
appended to the 3’end of the gene(s) to generate reference sequences. Unlike with 
3’RACE-seq reads, where the start of the linker marked the precise position of the gene’s 
end, here the linker merely indicates that the end of the gene is at or downstream of the 
mapping location of the read.  Hence, reads spanning the gene-linker junction collectively 
encompass 3’ RNA extensions, both adenylated and genomic, as well as potential genomic 
and other types of contamination.  The relative abundance of these reads was then 
compared across the genotypes. 
 
Statistical analyses. Singlepoint parametric linkage was analyzed using logarithm of the 
odds scores.  qRT-PCR analyses were reported as standard error of the mean (s.e.m.), and 
P values were calculated using GraphPad Prism software.  For each PCR run, samples were 
done in triplicate.  All P-values shown are two-sided. Statistical tests uses are indicated in 
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